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Abstract
LuxturnaTM is a retinal gene therapy treatment for an inherited retinal degeneration (IRD) caused by
mutations in RPE65, a gene that encodes for an enzyme involved in the visual cycle. RPE65 cDNA is
delivered subretinally using recombinant adeno-associated virus (rAAV) and successfully improves visual
function in patients diagnosed with Leber’s congenital amaurosis (LCA), a group of severe hereditary
retinal degenerations. Despite the success of LuxturnaTM, there remain several challenges to the
development of new retinal gene therapies. Here, I’ve focused on solving several of these limitations,
including evaluating the safety of same eye AAV readministration, manipulation of the gene transfer
vector, and development of an in vitro IRD model. Readministration of AAV to the same retina may be
desirable in order to treat additional areas not targeted during the initial injections or to boost transgene
expression levels at a later timepoint in areas of the retina that have already been transduced. However,
safety and efficacy concerns regarding an inflammatory immune response to the viral capsid upon
readministration have kept us from exploring the possibility of successive injections. We administered
bilateral subretinal injections of 1E11 vg rAAV2-hRPE65v2 to three unaffected non-human primates and
then delivered repeat subretinal injections in those same eyes two months later. Serial ophthalmic exams
were carried out during the course of the study. Peripheral blood monocytes and serum samples were
collected at baseline and post-injection timepoints to characterize the cellular and humoral immune
responses. In addition, we have identified an AAV8BP2 capsid variant through rational mutagenesis of a
tyrosine residue that is able to transduce retinal bipolar cells more efficiently than the parent serotype.
Our ability to do so may be integral for development of optogenetic treatment options for cases of severe
photoreceptor degeneration in which the usual machinery must be bypassed. Additionally, we assessed
the utility of patient-specific induced pluripotent stem cells to model early CRB1-associated LCA. All three
of these findings allow us to confront the current assumptions in the field and expand our toolbox for
developing new and modifying existing AAV retinal gene therapies.
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ABSTRACT

ADDRESSING AAV-MEDIATED GENE THERAPY CHALLENGES IN THE RETINA:
READMINISTRATION, AAV CAPSID OPTIMIZATION, AND IN VITRO DISEASE MODELING

Lindsey Sonja Weed
Dr. Jean Bennett

LuxturnaTM is a retinal gene therapy treatment for an inherited retinal degeneration
(IRD) caused by mutations in RPE65, a gene that encodes for an enzyme involved in the
visual cycle. RPE65 cDNA is delivered subretinally using recombinant adeno-associated
virus (rAAV) and successfully improves visual function in patients diagnosed with Leber’s
congenital amaurosis (LCA), a group of severe hereditary retinal degenerations. Despite
the success of LuxturnaTM, there remain several challenges to the development of new
retinal gene therapies. Here, I’ve focused on solving several of these limitations, including
evaluating the safety of same eye AAV readministration, manipulation of the gene transfer
vector, and development of an in vitro IRD model. Readministration of AAV to the same
retina may be desirable in order to treat additional areas not targeted during the initial
injections or to boost transgene expression levels at a later timepoint in areas of the retina
that have already been transduced. However, safety and efficacy concerns regarding an
inflammatory immune response to the viral capsid upon readministration have kept us
from exploring the possibility of successive injections.

We administered bilateral

subretinal injections of 1E11 vg rAAV2-hRPE65v2 to three unaffected non-human
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primates and then delivered repeat subretinal injections in those same eyes two months
later. Serial ophthalmic exams were carried out during the course of the study. Peripheral
blood monocytes and serum samples were collected at baseline and post-injection
timepoints to characterize the cellular and humoral immune responses. In addition, we
have identified an AAV8BP2 capsid variant through rational mutagenesis of a tyrosine
residue that is able to transduce retinal bipolar cells more efficiently than the parent
serotype. Our ability to do so may be integral for development of optogenetic treatment
options for cases of severe photoreceptor degeneration in which the usual machinery must
be bypassed. Additionally, we assessed the utility of patient-specific induced pluripotent
stem cells to model early CRB1-associated LCA. All three of these findings allow us to
confront the current assumptions in the field and expand our toolbox for developing new
and modifying existing AAV retinal gene therapies.
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CHAPTER 1: INTRODUCTION

Lindsey S. Weed1

1. Cell and Molecular Biology Graduate Group and the F.M. Kirby Center for
Molecular Ophthalmology, Perelman School of Medicine, University of
Pennsylvania, Philadelphia, PA 19104, USA
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The retina
Structure and function
The retina is a neural tissue situated at the back of the eye made up of several
different specialized cell types

Cornea

that work together to convert

Pupil
Lens

the energy of light into an

Light
source

Vitreous

electrochemical stimulus that

Optic nerve

can be interpreted by the brain
(Figure

1.1).

Mammalian

retinal composition includes
five general types of neurons –
photoreceptors, bipolar cells,
ganglion cells, horizontal cells,
and amacrine cells – and one
type of glial cell – Müller glia –
organized into distinct nuclear
and

plexiform

layers.

Additionally, a pigmented cell
monolayer known as the retinal
pigment

epithelium

(RPE)

Figure 1.1. Illustration of retinal structure
Light enters the eye through the cornea and passes
through the pupil to the lens, which focuses light rays
through the vitreous to the retina at the back of the eye.
The photons of light are captured by the photoreceptors
triggering a signaling cascade. This action potential (red
arrows) is propagated by the bipolar cells and modified
by the horizontal and amacrine cells before reaching the
ganglion cells closest to the visual field. The ganglion cell
axons converge to form the optic nerve which carries the
nerve impulse to the visual cortex of the brain. Adapted
from https://discoveryeye.org/layers-of-the-retina/

structurally and metabolically
supports the underlying neurosensory retina (Young and Bok, 1969; Fulton and
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Rando, 1987; Quinn and Miller, 1992; Seagle et al., 2005; Strauss et al., 2005).
The primary light-sensing cells are the rod and cone
photoreceptors, named in part due to their unique
structure. The axon terminal is situated closest to the
visual field followed by the cell body, which contains
the organelles. This is trailed by the inner segment
and finally the outer segment – the part of the
photoreceptor responsible for capturing light. The
outer segment contains disks filled with light
absorbing protein, opsin, and voltage-gated sodium
Figure
1.2.
Schematic
representation of rod and
cone photoreceptors
Each type of photoreceptor
consists of three regions: the
outer segment, the inner
segment, and the synaptic
terminal. The outer segment is
made up of membranous discs
that
contain light-capturing
photopigments. Adapted from
http://what-whenhow.com/neuroscience/visualsystem-sensory-system-part-2/

channels (Figure 1.2; Worthington, 1973).

Opsin is bound to a pigment molecule known as
retinal, a derivative of vitamin A. In rod cells, this
combination is known as rhodopsin. Rhodopsin is
extremely sensitive to light and therefore enables
vision in dim light (Schultze, 1867). On the other

hand, cone cells contain three different types of opsin that form photopsins with
retinal. These three classes of photopsins absorb light at different wavelengths and
require significantly brighter light to produce a signal. Thus, color experience and
visual acuity is calculated from these distinct cones (Schultze, 1867). Within the
human retina, rods outnumber cones 20:1 (Purves et al., 2011). Rods and cones
are intermingled with the exception of the fovea, the very center of the field of
3

vision, which contains the largest concentration of cones and is the region
responsible for producing the highest visual clarity.

Phototransduction
Phototransduction is the pathway by which the energy of light photons leads to
electrical polarization of the photoreceptor cells (Arshavsky et al., 2002). When
these cells are not being stimulated, they contain a high concentration of cyclic
guanosine 3’-5’ monophosphate cGMP, which opens ion channels, allowing
positively charged ions to enter the cell and depolarize the membrane. In turn,
neurotransmitter glutamate is continuously released from the axon terminal to
bipolar cells. Upon light stimulus, absorption of photons causes a conformational
shift in the visual pigment that confers strong binding potential to membrane-bound
G protein, transducin (Figure 1.3A; Gröbner et al., 2000). Transducin then
activates enzyme phosphodiesterase (PDE) to catalyze the hydrolysis of cGMP to
5’ GMP (Figure 1.3B, C). The net reduction of intracellular cGMP closes ion
channels and causes the photoreceptor outer segment to become hyperpolarized
(Figure 1.3D). Subsequently, less glutamate is released at the synaptic cleft
between photoreceptors and bipolar cells

4

B

A

D

C
Figure 1.3. Schematic diagram of the events involved in phototransduction in rods
(A) Light stimulation of retinal photopigment rhodopsin (or photopsin in cone photoreceptors)
activates G-protein transducin. (B) Transducin subsequently activates phosphodiesterase
(PDE). (C) PDE hydrolyzes cGMP, reducing the intracellular concentration. (D) This net
reduction of cGMP causes closure of Na+ channels, hyperpolarizing the outer segment.
Adapted from http://what-when-how.com/neuroscience/visual-system-sensory-system-part-2/

Bipolar cells of the retina exist as either off-center or on-center and respond
differently to low concentrations of glutamate (Figure 1.4). Further complexity
arises from the interconnections of horizontal and amacrine cells which modify the
synaptic signal before it is transmitted to retinal ganglion cells. In total, this diversity
is important for conveying different sorts of information to the same ultimate target
in a parallel manner. Finally, this nerve impulse is transmitted to the optic nerve at
the back on the eye and to the rest of the central nervous system.

5

Figure 1.4. Response of retinal bipolar and ganglion cells to darkness and illumination
There are two populations of bipolar cells synapsed to each photoreceptor that exhibit differing
graded potentials upon illumination. (A) In darkness, constant glutamate release from the
terminal photoreceptor synapse causes on-center bipolar cells to become hyperpolarized and
off-center bipolar cells to depolarize. Depolarization in this scenario leads to an action potential
in off-center ganglion cells. (B) Conversely, illumination of the receptive field decreases
glutamate release, depolarizing on-center bipolar cells and subsequently increasing the firing of
on-center ganglion cells. Adapted from http://what-when-how.com/neuroscience/visual-systemsensory-system-part-2/
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Inherited retinal degeneration
Disease genes and their associated cellular function
Given the incredibly complex and coordinated nature by which the retinal neurons
process light stimuli, very small defects in numerous processes can mediate very
dramatic results on visual function. Although blindness can be caused by opacities
that prevent light from reaching the photoreceptors and a number of other
infectious, neovascular, and metabolic conditions, here we will focus on inherited
retinal degenerations (IRDs). IRDs encompass a spectrum of chronic disorders of
visual function due to
mutations

in

genes

expressed in the neural
retina

and

retinal

pigment epithelium and
can
Figure 1.5. Relative quantification of the disruption of
cellular processes known to cause retinal degeneration
While several retinal disease genes are associated with specific
visual function processes, including phototransduction and the
visual cycle, disruption of many basic and ubiquitous cellular
processes can also lead to retinal dystrophy. Adapted from
Wright el al., 2010.

be

broadly

categorized

as

monogenic

or

multifactorial. The first
retinal

disease

gene

was identified in the early 1980s, but it wasn’t until such technological
advancements such as sequencing and the human genome project that we were
able to rapidly map more disease genes to the genome (Nussbaum et al., 1985).
Today, over 270 genes that can lead to vision loss have been identified (RetNet,
the Retinal Information Network). With the exception of some families that exhibit
7

complex inheritance patterns, most forms of hereditary retinal degeneration have
classical inheritance patterns, including autosomal recessive, autosomal
dominant, X-linked, or mitochondrial (Rivolta et al., 2002).

As expected, many retinal disease genes are associated with components
involved in phototransduction or the visual cycle, impeding the detection of light
and/or transmission of the light signal to the brain. However, more surprisingly,
there is incredible functional diversity in genes with respect to basic and ubiquitous
cellular processes, including splicing, transport, and cell signaling (Figure 1.5;
Wright et al., 2010). For example, PRPF31 encodes for the splicing factor PRP31,
which is essential for the formation of the spliceosome (Vithana et al., 2001).
Although pre-mRNA processing occurs in every cell type of the body, mutations in
PRPF31 are only known to cause retinal dysfunction. One possible explanation for
this phenomenon may be the autosomal dominant inheritance pattern of the
disease, which may produce enough functional PRP31 from the wild-type allele to
splice pre-mRNA in other cell types without problem, but is unable to sustain the
high volume of processed pre-mRNAs in the retina (Tanackovic et al., 2011).

Clinical phenotypes
IRDs are typically classified into two phenotypes – rod-cone and cone or cone-rod
dystrophy (RCD, CD, and CRD, respectively). These subtypes differ in the manner
that they affect rod or cone photoreceptors. In rod-cone dystrophies, primary loss
of rods always leads to secondary loss of cones. This is observed clinically by night
8

vision impairment preceding loss of visual field and acuity. In cone-rod dystrophies,
the rarer of the two subtypes, the onset of symptoms occurs in reverse of those
observed in RCD, although rod loss doesn’t necessarily always follow cone loss
as observed in CD. Ultimately, end-stage IRDs are almost indistinguishable from
one another, both culminating in severe degeneration and loss of vision.

The most common IRD, retinitis pigmentosa (RP), affects approximately 1 in 4000
people and can be caused by mutations in more than 50 genes (Ferrari et al.,
2011). RP can occur by itself or beside various syndromic disorders. It is an RCD
with symptoms that typically appear in childhood beginning with loss of night vision
and progressing to tunnel vision with the development of peripheral blind spots
(Figure 1.6). The pace of retinal degeneration varies with the causative gene. It
can take years or decades for atrophy to progress toward the cone-dense macula
at the center of the visual field. In the most severe cases, dysfunction and

degeneration begin before birth and lead to complete blindness within the first two
Figure 1.6. Progressive loss of visual field in retinitis pigmentosa
As rod photoreceptors begin to degenerate, RP patients lose peripheral vision. Over time, retinal
atrophy progresses towards the center of the retina, which contains the highest concentration of
cone photoreceptors. This tunnel vision eventually gives way to total blindness upon secondary
degeneration of cones. Adapted from http://www.acucela.com/diseases/rp/index.html
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decades of life (Chung and Traboulsi, 2009). This congenital form of RP is known
as Leber’s congenital amaurosis (LCA). Although a distinction is sometimes made
between early onset RP and LCA, the symptoms and clinical progression are very
similar.

Conversely, initial symptoms of CRD include a decrease in visual acuity and
photophobia. These signs typically appear in childhood and are followed by blind
spots in the central field of vision, loss of color perception, and finally loss of
peripheral vision. As mentioned above, rod loss doesn’t necessarily always follow
cone loss. Cone-dystrophy (CD) can be broken down into two broad categories –
progressive and stationary (Simunovic and Moore, 1998). In the case of
progressive CD, the symptoms are the same as CRD with the exception of
peripheral vision preservation. These symptoms become worse over time. In
stationary CD, symptoms are usually present at birth or early childhood, but tend
to remain stable over time. As in RCD, severity and progression vary greatly from
person to person.

10

Gene therapy for IRDs
A brief history
Conceptually, gene therapy is incredibly simple: if we know the underlying genetic
deficit of an inherited disease process, can we devise a strategy to deliver healthy
versions of the
defective gene
to the cell types
exhibiting

the

pathology as a
way to halt or
reverse disease
Figure 1.7. Schematic of gene therapy as a concept
A vector containing a functional version of a defective gene is used to
deliver this therapeutic cargo to a diseased cell where expression of the
gene will produce functional protein to halt or reverse the disease process.

progression
(Figure

1.7).

This

idea

initially arose in the 1960s and gained traction in the early 1970s with the
development of characterized cell lines that could be used to test the introduction
of foreign DNA to create stable, heritable genetic changes (Friedman, 1992).
However, our limited understanding of gene expression and the inefficiency of
early gene transfer methods left much to be desired.

It soon became clear that expression of exogenous genetic information was more
effective with polyomavirus SV40, which could stably integrate into the genomes
of target cells (Sambrook et al., 1968; Hill and Hillova, 1972). The final piece of the
11

puzzle came with the advent of recombinant DNA techniques, which allowed
scientists to modify viruses to incorporate foreign genes. What followed was an
unapproved and unsuccessful attempt at human gene therapy targeting
thalassemia that catalyzed questions regarding the science, ethics, and public
policy behind the nascent field (Wade, 1980; 1981; 1981). Despite this, it was soon
demonstrated that retroviral vectors could be used to successfully correct disease
phenotypes in vitro (Miller et al., 1983).

In 1990, the first patient to receive an approved gene therapy had her own ex vivomodified white blood cells reinfused to test the treatment of adenosine deaminase
severe combined immune deficiency (ADA-SCID). A retrovirus was used to
transfer the ADA gene to the isolated T cells. This landmark clinical trial was
headed by French Anderson, now known as the father of modern gene therapy.
There was genuine excitement for the future of the field when significant, yet
temporary, health improvements were observed. However, two major setbacks
occurred between 1999 and 2003. Adenovirus (Ad) was beginning to be
recognized as another possible viral vector for gene transfer. The employment of
Ad to target the liver in a clinical trial at the University of Pennsylvania to treat an
individual with a relatively mild form of ornithine transcarbamylase (OTC)
deficiency, a disease that is usually lethal in babies, resulted in the death of a
young patient (Raper et al., 2003). In the aftermath, a number of flaws in the
consent process were discovered. Additionally, the FDA halted all trials using
retroviral vectors after two patients treated for ADA-SCID developed leukemia
12

(McCormack and Rabbitts, 2004). There was a serious need to address vector
delivery, as well as ethical and safety issues if gene therapy was to move forward
in any clinical setting.

Adeno-associated virus
The spectrum of viral vectors considered for use in gene therapy is very broad and
includes both viruses with DNA and RNA genomes. This range provides a host of
features that are favorable for varying diseases when the transgene, the target
organ or cell type, and the nature of the disorder is taken into consideration. It is
worth mentioning there are also a number of non-viral vectors although those
generally do not confer stable expression. However, for this discussion I will be
focusing on the use of AAV as it is currently the preferred vector for IRDs.

AAV is a small, replication-defective, nonenveloped, single-stranded DNA
(ssDNA) virus that was first observed in Ad preparations and originally believed to
be a contaminant (Atchison et al., 1965). The genome contains two open reading
frames flanked by inverted terminal repeats (ITRs) (Figure 1.8A). The open reading
frames encode for genes Rep and Cap, which are translated to produce multiple
proteins required for the AAV life cycle. By itself, wild-type AAV (wtAAV) is
replication deficient and requires proteins supplied by another virus, such as Ad or
herpes simplex virus (HSV) for lytic cycle activation (Gonçalves, 2005).

13

When using AAV as a gene transfer vector, Rep and Cap are removed from the
plasmid and replaced with various transgene elements, including a promoter, a
gene of interest, and a polyA signal (Figure 1.8B). The ITRs are conserved in the
expression cassette as they are involved in the packaging of the recombinant
genome into the viral capsid. To create useable, infectious recombinant AAV
(rAAV) particles, Rep and Cap in addition to an Ad helper plasmid must be supplied
in trans with the recombinant plasmid as a triple transfection into HEK293 cells.

A
B

Figure 1.8. Wild-type AAV genome in comparison to recombinant AAV expression cassette
(A) The wild-type AAV genome contains genes Rep and Cap that produce proteins essential for
AAV replication and encapsidation flanked by inverted terminal repeats. (B) Recombinant AAV is
made by removing the Rep and Cap genes and replacing them with an expression cassette that
includes the transgene and other necessary elements to promote efficient gene expression.

Advantages
AAV has become the gold standard for transferring genes to various tissue
populations in vivo due to its lack of pathogenicity, stable transgene expression in
nondividing cells, relatively low immunogenicity (in a context dependent manner),
and episomal persistence (Rolling and Samulski, 1995; Flotte et al., 1994; Duan
et al., 1998). As part of its lysogenic cycle, wild-type AAV integrates into the human
host genome in the AAVS1 site on chromosome 19 (Kotin et al., 1990; Samulski
et al., 1991; Linden et al., 1996). However, because rAAV is made with the Rep
14

gene in trans, the ability to integrate is all but abolished. Instead, rAAV becomes a
double-stranded,

circular

extrachromosomally,

episome

limiting

the

in

the

potential

nucleus
of

that

insertional

is

maintained
mutagenesis

(Ponnazhagan et al., 1997). In the presence of DNA damage, rAAV can integrate
into the host genome, but this occurs at a frequency of less than 0.1% (Yang et
al., 1997; Miller et al., 2002). Episomal stability confers long-term transgene
expression in quiescent cell populations. Although rAAV has the ability to
transduce both dividing and nondividing cells, the episome is lost during division
and therefore is more well-suited for post-mitotic cells in the context of persistent
expression (Calos, 1996).

Additionally, AAV comes in a variety of naturally-occurring serotypes that differ in
their tropism making it a valuable tool for preferentially transducing specific tissues
or cell types. Specificity reduces the risk of immunogenicity and systemic
expression of transgenes. The icosahedral AAV capsid serotypes have differing
surface topology and subsequently interact with distinct cell surface receptors or
domains of glycan moieties to be endocytosed (Pillay et al., 2017). Scientists have
also developed strategies to create hybridized serotypes in the laboratory,
expanding our ability to precisely target tissue or cell populations of interest.

Limitations
As with all gene transfer vectors, AAV has limitations. Due to its size, the packaging
capacity of AAV is very small – approximately five kilobases (kb). When one
15

considers the necessary expression cassette elements needed to confer
constitutive expression at therapeutic levels, the size of the transgene is confined
to usually less than four kb, much smaller than many recognized disease genes.
Secondly, rAAV can cause humoral and cellular immune responses to the capsid
when administered systemically (Mingozzi and High, 2013). This constrains the
potential for readministration and makes the need for stable, lifelong transgene
expression even more critical. Furthermore, patients that have been exposed to
wild-type AAV and have high neutralizing antibody titers are more likely to be
excluded from receiving AAV-mediated gene therapy because of the likelihood of
developing an adverse immune reaction. Lastly, the production and purification
process of AAV is extensive and expensive, particularly when made on a large
scale. Many considerations regarding the patient population, including natural
history of the disease, target tissue, mode of inheritance, and specific gene
mutation, must be made when developing a therapy.

Favorable features of the eye
The eye has been a focus of gene therapy for several reasons. Firstly, it is a very
well-studied organ. Many of the key processes and mechanisms by which vision
is mediated are better understood than the key pathways of our other senses. This
is in part due to its surgical accessibility and the ability to use noninvasive in vivo
imaging and functional techniques both to study the biology of the eye and to
evaluate safety and efficacy in animal models and humans after administration.
16

Secondly, the eye is small and self-contained. In comparison to larger organs, a
small amount of vector is needed for efficient distribution, which minimizes the
potential for vector-associated toxicity. Moreover, the structure of the retina, which
includes tight junctions between the RPE cells as part of the formation of the bloodretinal barrier, prevents vector dissemination beyond the eye and gives rise to
ocular immune privilege, a process which can suppress a harmful immune
response. The immunologically favorable ocular environment is composed of cellbound and soluble immunosuppressive factors that directly act on immunecompetent cells (Zhou and Caspi, 2010).

Lastly, retinal cells are post-mitotic, allowing for persistent transgene expression.
Thanks to the availability of numerous spontaneous and genetically engineered
animal models of retinal degeneration, gene therapy preclinical trials have been
greatly accelerated in comparison to diseases of other tissues. Additionally, the
symmetric nature of retinal dystrophies provides an internal control to assess the
effects of gene therapy compared to untreated or control-injected eyes.

LuxturnaTM
Prior to December 2017, there were no available treatments for IRDs. At that time,
LuxturnaTM, a gene therapy treatment for LCA caused by mutations in RPE65
(LCA2), was approved by the Federal Drug Administration (FDA). RPE65 is an
isomerohydrolase expressed in the RPE that mediates the necessary conversion
17

of all-trans retinal to 11-cis retinal during the visual cycle (Redmond et al., 1998;
Redmond et al., 2005; Jin et al., 2005; Moiseyev et al., 2005). LuxturnaTM delivers
the human RPE65 cDNA using recombinant adeno-associated virus serotype 2
(rAAV2).

In order to qualify to receive LuxturnaTM, LCA2 patients must have mutations in
both copies of RPE65 in addition to having a substantial number of remaining
photoreceptors in order to benefit from the therapy. The treatment is delivered
subretinally to both eyes, targeting the RPE localized in the outer retina. The
injection cannula is surgically placed between the RPE and the inner retina before
the vector solution is slowly delivered, creating a localized detachment known as
a bleb. Over a period of a few hours to a few days the neural retina reattaches to
the RPE.

In clinical trials, 95% of patients that received LuxturnaTM showed improvement in
their ability to navigate through a Multi-Luminance Mobility Test course at least two
light levels darker than prior to treatment (Russell et al., 2017). LuxturnaTM is
successful at treating LCA2 patients in part because the progression of
degeneration is relatively slow, allowing for greater numbers of remaining
photoreceptors to reap the benefits after the treatment. Additionally, each
transduced RPE cell subserves multiple photoreceptors, amplifying the effect of
intervention (Snodderly et al., 2002). Lastly, the enzymatic nature of RPE65
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appears to require only a critical amount of protein to correct the underlying
disease and excess RPE65 has not been observed to be harmful to the retina.
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Challenges to development of novel retinal gene therapies
Despite the clinical success of LuxturnaTM and the establishment of a platform for
developing new treatments targeting other forms of IRD, there remain several
challenges. This section will attempt to summarize these issues and present some
possible solutions.

Unknown genetic diagnosis and incomplete natural history
Although we have pinned down many of causative retinal disease genes, there still
remains a rather large percentage of
patients

with

IRDs

that

have

underlying genetic defects yet to be
identified (Figure 1.9; den Hollander
et al., 2008). Additionally, many
studies of the disease course of
IRDs,

from

onset

to

eventual

resolution, are incomplete. This, in

Figure 1.9 Relative quantification of LCA
patients with mutations in known and
unknown retinal disease genes
While we have identified the majority of LCAassociated genes, there still remains a large
proportion of patients with an unknown genetic
cause. Adapted from den Hollander et al., 2008.

part, is due to heterogenous disease presentation, even among patients with the
same mutations, suggesting many of the IRDs we believe to be monogenic may
actually be multifactorial in nature, including other modifying alleles and
environmental factors that are significant for the presentation and progression of
these diseases. Knowledge of the natural history of disease is essential for
developing novel, efficient treatment strategies.
Limitations of gene transfer vectors
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As mentioned previously, AAV has biophysical limitations that prevent the
packaging of genes larger than five kb. One example of this problem happens to
be the most frequently mutated gene in LCA patients, CEP290, a centrosomal
protein important for cilia development. The coding sequence is approximately 8
kb, making it much too large to package into AAV. Among some of the attempted
approaches for this problem are the use of dual vectors, whereby a transgene is
split across two separate AAV vectors and both must transduce the same cell to
produce a functional protein, and pre-mRNA trans-splicing, which uses only a
portion of the gene to target and replace the defective fragment after transcription
to mRNA to produce a functional protein (Pergolizzi et al., 2003; Dooley et al.
2018). Both of these methods have thus far proven inefficient at correcting disease
phenotypes.

On occasion, the constitutive promoters that are often used to reach therapeutic
levels of protein expression can actually have negative consequences. Such is the
case with broad spectrum retinal gene therapies, which are attractive for their
ability to treat multiple causes of retinal degeneration by targeting upstream
signaling pathways, but may also lead to toxicity if uncontrolled. More sophisticated
regulatory elements are required to aid in dose delivery and promote safety. In this
instance, an inducible promoter would be desirable. Tetracycline (Tet) inducible
expression, a bacterial system developed from E. coli, is efficient in mammalian
cells in vitro and has demonstrated a lack of a humoral immune response when
injected in immune privileged sites (Han et al., 2010). However, Tet-inducible
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systems have demonstrated loss of inducibility when silenced for extended
intervals, requiring continuous induction to prevent silencing and all but abolishing
its usefulness (Yu et al., 2016). Given the immune response to rAAV
readministration, more preclinical testing with inducible promoters is required.

Although the use of different naturally occurring and hybridized AAV serotypes has
greatly enhanced our ability to target specific tissues and cell types, there still
remains retinal cell populations with low or no AAV transduction efficiency. In this
instance, the answer has been to continue to create new capsids. One method
that has been rather successful is directed evolution. By creating and screening a
library of repeatedly mutagenized recombinant Cap genes for infectivity and
cellular tropism, it is possible to create an AAV capsid that targets cells which were
once impenetrable to transduction or to increase the transduction efficiency.

Complex inheritance patterns and disease presentation
IRDs display enormous genetic and clinical heterogeneity. This feature often
makes it difficult to discern patient populations that may benefit from gene therapy.
Often, mutations in the same gene can cause a range of clinical phenotypes
whereas similar phenotypes can denote end-stage disease as the result of many
different genes. Therefore, clear genotype-phenotype correlations are frequently
unable to be made, as is the case with patients that harbor mutations in PRPF31.
Although inherited in an autosomal dominant manner, there appears to be partial
penetrance at play, manifesting as dominant mutations that appear to not cause
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disease. This is thought to be due to the presence of wild type alleles that differ in
expressivity – some are highly expressive while others are not (Rose and
Bhattacharya, 2016). If a patient has a mutant allele but also has a highexpressivity allele, they produce enough protein to reach a threshold in which they
fail to display the disease phenotype. On the other hand, if the patient has a lowexpressivity allele along with the mutant allele, the amount of functional protein
produced falls below the threshold, causing disease presentation.

The phenotype and kinetics of degeneration can vary greatly with the severity of
the mutation. Patients with mutations that encode for early stop codons experience
nonsense-mediated decay of the transcribed mRNA and produce no functional or
partially functional protein, whereas a patient with a single base substitution may
maintain protein translation. This must be accounted for when considering
candidates for gene augmentation due to the possibility of an immune response to
the transgene. A patient that is naïve for the transgene protein product is more
likely to develop an immune response to this “foreign” antigen in comparison to a
patient that produces a nonfunctional protein product.

Different variants of interacting partners of the deficient protein can also alter the
clinical phenotype. These are known as modifying alleles and they may exert
different influences that are all but undetectable without genome wide association
studies, which require thousands of patients to produce significant results. Multiple
mutations of disease genes further complicate this scenario. Furthermore,
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genetically unaffected cell types, such as cones in RP, degenerate secondarily to
rods, suggesting rods produce some necessary survival factor for cones. In total,
this heterogeneity combined with our lack of understanding regarding certain
disease mechanisms makes the need for broad spectrum therapeutic approaches
crucial.

Pre-clinical developmental hurdles
Even given our ability to create expression cassettes for many different disease
genes and access to suitable AAV vectors for target retinal cells, the field still lacks
many of the tools needed to answer basic research questions and test these novel
gene therapies. Likely the leading impediment to the creation of novel IRD gene
therapies is the lack of stable photoreceptor and other retinal cell lines. Without
these cultures we are limited in our capability to understand the very fundamentals
of IRD etiology and progression. Furthermore, this subjects researchers to
discrepancies between gene transfer vector activity in cell-based systems and in
vivo. Lastly, several of the disease genes lack animal models that display relevant
ocular phenotypes. Animal models that do have phenotypes don’t always predict
treatment outcomes in humans. Thus, it is not always clear how one can obtain an
accurate assessment of safety and efficacy of a reagent before going to human
studies. Moreover, only primates replicate human macular structure. To date, only
one NHP has been identified with an IRD (a form of achromatopsia), so results
from most spontaneous and genetically engineered animals cannot be
extrapolated for treatment of macular disease.
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Concluding thoughts
I was lucky to begin my dissertation in a field that was successfully moving forward
at a rapid pace. Addressing even one of these numerous challenges feels like a
huge personal and professional accomplishment, despite also feeling like solving
one problem creates a whole host of other obstacles. These thought-provoking
questions are what continue to pique my interest, even as I leave lab for the night,
even as I relax into the evening, even when I lay down to sleep.

I hope this introduction has provided a thorough background of the retina, the
hereditary diseases that plague it, and the gene augmentation treatments that
have and are yet to be developed. The future of the field heavily depends on finding
solutions to the issues presented here and it is my intent to showcase the work I’ve
done that lends itself to some of these concepts. Within the next three chapters, I
will provide a more in-depth overview and analysis of several of these ideas, and
it is my hope that the common threads connecting each of these projects clearly
demonstrates my wonder and passion for understanding the building blocks of life
and how this miniscule matter can be manipulated to breed enormous impact.
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Abstract
We have previously shown that subretinal readministration of rAAV to the
contralateral eye in large animals and humans is safe and effective, even in the
setting of preexisting neutralizing antibodies (NAbs). Readministration of AAV to
the same retina may be desirable in order to treat additional areas of the retina
that were not targeted in the initial injections or to boost transgene expression
levels at a later timepoint in areas of the retina that have already been transduced.
Therefore, a better understanding of the immune responses and structural
consequences of subretinal rAAV readministration to the same eye is necessary.
We administered bilateral subretinal injections of rAAV2-hRPE65v2 to three
unaffected non-human primates and then, two months later, carried out repeat
subretinal injections in those same eyes. Serial ophthalmic exams were carried out
during the course of the study. Retinal imaging was carried out following the first
and second injections. Peripheral blood monocytes (PBMCs), serum, and
intraocular fluids were collected at baseline and post-injection timepoints to
characterize the cellular and humoral immune responses. Finally, histopathologic
and immunohistochemical studies were carried out on the treated retinas. The
repeat injections were generally immunologically and structurally well-tolerated,
even in the setting of preexisting serum neutralizing antibodies (NAbs). Ipsilateral
readministration of AAV2-hRPE65v2 in no human primates was safe. Localized
structural abnormalities confined to the outer retina and RPE after readministration
of the treatment do not differ from those observed after single or contralateral
administration of this therapy.
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Introduction
Inherited retinal dystrophies (IRDs) encompass a large molecularly and clinically
heterogeneous group of conditions caused by mutations in genes expressed in the
neural retina and retinal pigmented epithelium (RPE). To date mutations in over
270 genes have been reported to cause various IRDs ranging in severity from mild,
gradual, late onset of vision loss, to blindness soon after birth (Verbakel et al.,
2018; Wright et al., 2010; Weleber et al., 2013). Until very recently, there was no
available treatment for IRDs. The US Food and Drug Administration (FDA) and the
European Medicines Agency (EMA) recently approved AAV2-hRPE65v2
(Luxturna™, voretigene neparvovec-rzyl, Spark Therapeutics Inc., PA, USA) for
subretinal delivery as gene augmentation treatment for an early onset, autosomal
recessive IRD caused by bi-allelic RPE65 mutations. LuxturnaTM carries the
wildtype version of the human RPE65 cDNA driven by a constitutive chicken βactin with a cytomegalovirus enhancer promoter packaged in recombinant adenoassociated virus serotype 2 (rAAV2) and delivered to the tissue by subretinal
injection (Bennicelli et al., 2008; Russell et al., 2017; Maguire et al., 2008).

The subretinal injections typically lead to transduction of retinal cells only within
the area of the localized transient retinal detachment or ‘bleb’ that result (Bennett
et al., 1999). Thus, visual improvement, although impressive, is limited to the
location and extent of the treated region. Ipsilateral readministration of gene
therapy agents to the retina could be useful in a number of situations. A likely
scenario would be the need to treat additional areas of the retina not targeted
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during the initial injection, as the blebs do not predictably track to the region
planned for treatment pre-operatively. In other scenarios, fragile regions such as
the fovea may have been deliberatively spared over concerns of potential tissue
damage and potential central vision loss. In such scenarios, it may be desirable to
treat previously untreated regions at a later timepoint. Finally, if transgene
expression levels were to subside over time after a single injection,
readministration could be used as a booster in previously transduced cells
(Bainbridge et al., 2015; Jacobson et al., 2015).

Subretinal delivery of gene therapy agents is effective and relatively benign, in
large part due to the fact that the retina is an immunologically privileged site
(Bennett et al., 1996; Bennett, 2003; Anand et al., 2000). We have previously
shown that subretinal readministration of AAV2-hRPE65v2 to the contralateral eye
is well-tolerated and does not elicit an inflammatory immune response (Bennett et
al., 2016). Further, readministration to the contralateral eye results in the predicted
gains in retinal function both in affected dogs and in patients (Bennett et al., 2016;
Bennett et al., 2012; Amado et al., 2011; Annear et al., (2011). However, to our
knowledge, there are no reports of repeated delivery into an already injected retina.
The main concern is that a previously exposed eye may be better primed to mount
a potentially harmful immune response upon readministration of the vector
(Chirmule et al., 1999; Calcedo and Wilson, 2016). Therefore, a comprehensive
understanding of ocular immunogenicity to AAV vectors upon same eye
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readministration will be useful in defining the safety and feasibility of this
procedure.

Nonhuman primate (NHP) eyes are very similar in size, anatomical constituents
and proportions to human eyes, including the existence of a nearly identical
macular region. Further, the ocular immune response to AAV vector administration
in NHPs has proven a good predictor of the human immune response (Amado et
al., 2010; Jacobson et al., 2006). To determine the humoral and cellular immune
response to same eye subretinal readministration, we performed studies using
GMP-comparable rAAV2-hRPE65v2 (similar to LuxturnaTM) in healthy NHPs. We
carried out serial in-vivo multimodal retinal imaging after sequential subretinal
administration of the vector to the same eye in order to assess changes over time
that might correlate with the systemic and local immunologic profile and
histopathologic changes ex-vivo.
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Results
Effects of bilateral same-eye subretinal readministration of AAV2hRPE65v2 in NHPs
Evaluated were three unaffected NHPs ~7 to 8 years old at the start of the study
(Table 1). Two were cynomolgus and one was a rhesus macaque. All animals had
been studied previously in a pharmacology study that did not involve the eye and
their geographic origins were unknown. Subretinal injections of AAV2-hRPE65v2
were carried out bilaterally (Figure 2.1, Table 1). As expected based on our
previous studies, the retinal detachments had resolved by the first ophthalmoscopy
post-injection timepoint (3 days) (Amado et al., 2010; Bennett et al., 1999). There
were no cells in the anterior chamber or vitreous compartments. Pigmentary
changes delineating the borders of the detachments (“blebs”) were noted. Two
months later a second injection of similar volume and dose of AAV2-hRPE65v2
was delivered subretinally in a region that overlapped either completely or partially,
or avoided altogether the initial treatment region in order to observe any differing
effects between the three scenarios (Figure 2.1, Table 1). Visible “watermarks”
demarcating the boundaries of the first bleb and vasculature landmarks served as
landmarks for the readministration procedures. Pigmentary changes were present
in the regions of injection, with hyperpigmentation at the borders of the injected
region and hypopigmentation within the bleb in all eyes (Figure 2.2A). The changes
are visible by ophthalmoscopy and have been observed as early as 3 days after
the subretinal injections (data not shown). Fibrous metaplasia was also noted in
the inferior blebs of both eyes of 10C015. The blebs were located at a similar
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distance relative to the optic nerve in superior and/or inferior retina, although some
blebs extended into the central macula (Figure 2.1). The retina surrounding the
blebs appeared normal (Figure 2.2A). En-face retinal imaging with short
wavelength fundus autofluorescence (SW-FAF) serves to monitor the health of the
RPE,

and

indirectly

the

photoreceptors,

by

capturing

the

returning

autofluorescence (AF) signal produced by the excitation by blue light of lipofuscin
and melano-lipofuscin fluorophores within RPE cells (Kennedy et al., 1995;
Greenberg et al., 2013). After the initial injections, SW-FAF clearly delineates the
edge of the blebs (Figure 2.2B, Injection 1). The boundaries of the blebs appear
as variably hypo-autofluorescent arcs that can be traced until the peripheral edge
was out of reach to imaging. The SW-FAF outside of the bleb boundary showed a
normally homogeneous gray background in the midperiphery crossed by the dark
contour of the retinal vasculature as well as the dark hypo-autofluorescent foveal
center caused by absorption of the blue excitation light by the macular pigment
(Delori, 2004). Within the blebs there are striking changes with darker areas of
non-homogenous hypo-autofluorescence, some nearly circular, separated from
the linear hypo-autofluorescent edge of the bleb by a band of better appearing,
light gray, signal (for example, Figure 2.2B, Injection 1). SW-FAF imaging after
vector readministration in the eyes of the animal with the non-overlapping blebs
replicated the same pattern observed after the initial administration (Figure 2.2B,
Injection 2). Partial overlap of the injected regions (BF54F) resulted in merging of
the two blebs without a locally more severe loss of the autofluorescent signal within
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the overlapping section, whereas, the animal with complete bleb overlap (11D086)
showed denser hypo-autofluorescence within the bleb after readministration.

Spectral Domain Optical Coherence Tomography (SD-OCT) imaging was
performed as in vivo microscopy of the retina (Figure 2.2C). Topographic maps of
the thickness of the retina within the injected blebs performed after the initial
injection are very similar to maps generated after readministration suggesting no
major

changes

in

overall retinal thickness

occurred

after

same

eye

readministration for any of the three scenarios tested (non-overlapping, partially
overlapping, and totally overlapping blebs) (Figure 2.2C). Particularly, topography
maps straddling the boundary between uninjected and injected retina showed no
abrupt transitions in thickness (which would indicate thinning within the bleb) but
only a smooth transition to a thinner overall retina (cooler colors) which occurs
normally with increasing distance from the fovea (uninjected regions, Figure 2.2C,
Injection 1). Closer inspection, however, reveals there were local changes in
thickness within the blebs. Animal 10C015 shows an area of mild thickening in
superior retina after the initial administration that is less obvious following
readministration of the vector inferiorly (Figure 2.2C). This area corresponds to a
whitish lesion on fundus photography (Figure 2.2A). Animal BF54F shows a bandlike area of thickening superior to the nerve that also fades on follow up when the
readministered bleb partially overlaps with this region. Animal 11D086, who had
totally overlapping blebs following readministration, shows no differences in total
retinal thickness topography before versus after readministration. The site of the
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retinotomy which was used to reinject the same region can be still seen as a local
area of thinning highlighted in blue inferior to the nerve that turns slightly larger in
maps after readministration (Figure 2.2C).

Histologic and immunohistochemistry correlates of in vivo retinal
microscopy
To gain a better insight of the structural changes, single magnified SD-OCT crosssections from the readministration (injection 2) and initial administration (injection
1) areas were selected. These regions of interest (ROI) included uninjected retina,
boundary edge of the bleb, and areas that showed evident FAF abnormalities on
en-face imaging (Figure 2.2B). SD-OCT images were scaled and then aligned
using vascular elements so that the images would be comparable in magnification,
location, and orientation (Figure 2.3A). Nuclear layers (ONL, outer nuclear layer;
INL, inner nuclear layer; GCL, ganglion cell layer) can be seen running as parallel
hyporreflective bands bracketed by the highly reflective signals from the plexiform
layers (OPL, outer plexiform layer, IPL, inner plexiform layer) and the retinal nerve
fiber layer (RNFL), respectively (Figure 2.3A). The cross-section of superficial
large blood vessels shows a hyperreflective image with posterior shadowing
(Figure 2.3A, asterisk). Those were used to further align images from the first and
second injections. Photoreceptor structures distal to the external limiting
membrane (ELM) can be seen in cross-section, most noticeable among them at
these pericentral/midperipheral locations were the signals originating from the
inner segment ellipsoid band zone (EZ), the interdigitation between the tip of the
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photoreceptor outer segments (POS) and the apical RPE (IZ, band), and
RPE/Bruch’s membrane (BrM). All cross-sections used for this analysis were
located in near midperipheral supero-nasal and infero-nasal retina. At these
locations the cross-sectional profile is relatively flat allowing for comparisons of
relative thickness values of each of the retinal laminae between locations inside
the treated retina versus the surrounding untreated regions; the precise
registration of the images from each eye between consecutive experiments was
needed to assess for relative changes in thicknesses of each of the retinal
sublaminae between the two injections.

Qualitatively there were no obvious changes in any of the main nuclear, synaptic
layers or the RNFL layers in comparisons between uninjected and injected regions
in any of the eyes for any of the two experiments, or between the images taken
after readministration compared to the same locations on initial administration
(Figure 2.3A). However, closer inspection of the magnified SD-OCT cross-sections
revealed various degrees of outer retinal sublaminae changes in the injected
regions in most of the eyes. Changes included attenuation of the IZ and/or EZ band
signals accompanied in some areas of disruption of the RPE signal by
hyperreflectivities (for example, Figure 3A, animal BF54F). The changes occurred
in blebs resulting from both the initial and the readministered injections and were
apparently independent of the degree of overlapping of the blebs and of the degree
of abnormalities in en-face FAF imaging. For example, animal 11D086 with
overlapping injections and the most severe abnormalities on SW- and NIR-FAF
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imaging showed the least changes on SD-OCT imaging at the locations sampled.
Interestingly, re-emergence of the IZ band signal in 10C015 suggests some of the
abnormalities may be transient, indicating recovery of the POS anatomy with time
(Figure 2.2A). However, the disruption of the RPE band with apical
hyperreflectivities may represent RPE depigmentation, hypertrophy, or migration
and/or accumulation of subretinal inflammatory or degenerative debris.

At the time of necropsy, there were no abnormalities upon gross inspection in any
abdominal or thoracic organs or in the brain. Histologic retinal sections obtained at
study termination were chosen to closely match the locations represented in the
SD-OCT to help understand the significance of the in vivo observations (Figure
2.2B). The histopathologic picture confirmed preservation of the nuclear layers and
changes limited to the POS and the RPE consisting of examples of focal RPE
hypertrophy that explain irregular hyperreflectivities superficial to the RPE on SDOCT (Figure 2.3A and 2.3B animal BF54F, white arrows). All NHPs showed
dislodged or hypertrophic RPEs around the injection sites in at least one of their
eyes likely due to the mechanical nature of the injections. There was also mild
focal loss of RPE cells or replacement of RPE cells by fibrinoid scar and a rare
choroidal infiltrate (animal 11D86 OD) that closely resembled the SD-OCT findings
of loss of irregular hyperreflectivities superficial to the RPE (Figure 2.2A and 2.2B,
animal BF54F, white arrows). There were examples of loss of RPE cells with
replacement of RPE cells by fibrinoid scar and a rare choroidal infiltrate (Figure
S2.1; animal 11D86, OD). On histology, monkey 11D086, which had almost
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completely overlapping injections, displayed shorter, yet reattached, OS in some
areas, but those didn’t look disarrayed. Partially overlapping injection sites in
BF54F showed areas lacking OS in both eyes. Monkey 10C015 also had areas
lacking OS in each of the non-overlapping blebs, but had longer, cystic OS at the
first injection site in the right eye.

Histopathology was graded from mild to severe according the number and
distribution of inflammatory cells. Findings in NHPs BF54F and 11D086 were both
categorized as generally mild and presented with occasional localized pockets of
inflammatory cells in the choroid, but not in the subretinal space, suggesting these
infiltrates did not have an impact on the retinas. NHP 10C015 exhibited focal
infiltrates that spilled out partially into the subretinal space and therefore was
classified as severe. No inflammation in the vitreous or the anterior chambers was
observed in any of the animals. Quantitative SD-OCT parameters were used to
assess for changes in thickness of the total retina, inner retina and photoreceptor
ONL, as well as for the EZ-to-BM distance, a surrogate measure for POS length
(Figure 2.3C). The retinal cross-sections were segmented (see Methods, Figure
2.1) and thickness differences for each of the retinal laminae calculated either as
a fraction of the thickness value in uninjected retina or as a fraction of the thickness
value at the same location after the first injection. The aim was to facilitate
comparisons between animals by avoiding expected regional differences in
absolute thicknesses. In an initial approach the values were considered
significantly different if they exceeded by threefold the variability (3SD) of the
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estimates (SD = total: 2%; inner retina: 5%; ONL: 7%; EZ-BM: 6%) (Aleman et al.,
2017). There were no significant differences in thickness for total, inner or ONL
thicknesses for any of the injected retinas compared to the neighboring uninjected
retina or between the readministered regions compared to the initial administration,
confirming qualitative observations (Figure 2.3C). Differences in total retinal
thickness expressed as the fraction of the value measured after the initial injection
showed mild thinning, nearly identical in injected (mean difference ± 2SD = -3 ±
6%) and uninjected (-2% ± 6%) regions (i.e. inside vs outside injection blebs)
(paired t-test, P = 0.74). Similarly, the EZ-BM distance showed non-significant
thinning in both injected (-3 ± 13%) and uninjected (-6 ± 8%) (P = 0.63) retinas with
the variability for the estimates of the injected retina (Figure 2.3C, red bar) driven
by POS changes of animal BF54F. Comparisons between locations inside versus
outside the injected blebs at the first injection or second injection time points
(Figure 2.3C, gray and black bars) were more variable reflecting expected normal
topographic differences in thickness rather than real differences.

Outer retina and RPE changes after subretinal administration of AAV2hRPE65v2 in NHP but not in humans
Although there were no obvious differences in the structure of the inner retina and
photoreceptor nuclear layer (i.e. ONL) after the first or readministered injections,
there were changes in the POS and RPE that may not be readily visible on
histology. Multimodal, en-face retinal imaging with NIR-REF, NIR-FAF, and SWFAF, combined with colocalized cross-sectional in vivo histology with SD-OCT
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after the first injections were used to try to understand the origin of some of the
abnormalities by imaging large retinal regions which would not be easily sampled
with histology (Figure 2.4). The contour of the injected bleb was not visible on NIRREF on animal 10C015, whereas they could be clearly seen in animals BF54F and
11D086 as round lighter areas of hypo-reflectance delimited from the uninjected
retina outside of the bleb by a dark band. On NIR- and SW-FAF there was mottled
hypo-autofluorescence near the center of the blebs indicative of loss of melanin
within RPE cells or loss of RPE cells and/or photoreceptors. Whereas the areas of
abnormal FAF co-localized within the blebs using both excitation lights (NIR and
SW), the area of NIR hypo-AF tended to be granular, more central not reaching
the edge of the bleb, whereas on SW-FAF an abnormal hypo-AF signal may be
tracked to the edge of the bleb (for example, Figure 2.4, animal BF54F). The center
of these lesions on SW-FAF alternates normal (or hyper-FAF) with localized hypoAF, conferring the lesions a mottled appearance. Smaller circular contours or rings
that are eccentric in relationship to the center of the bleb can be seen in one of the
animals (Figure 2.4, animal 11D086). Magnified SD-OCT cross-sections across
the transitional margin of AF changes revealed that the loss of the SW-FAF near
the edge corresponds to the initial loss or attenuation of the IZ signal, whereas the
loss of both NIR-FAF and SW-FAF signals correspond to the loss of the IZ signal
and disruption of the RPE band (for example, Figure 2.4 BF54F) suggesting an
abnormal POS near the periphery of some blebs associated to loss of melanin
within the RPE for more central regions. There were intraretinal hyperreflective
tracks on SD-OCT above the RPE hyperreflectivities in BF54F which may
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correspond to intraretinal pigment migration (Figure 2.4, BF54F, circled). Of note,
some of the hyper-FAF signals on SW-FAF corresponded to the presence of
material above the RPE (Figure 2.4, animal 10C015, asterisk), whereas animal
11D086 shows minimal to no changes SD-OCT changes despite obvious hypo-AF
on NIR- and SW-FAF. Immunohistochemical analysis using anti-RPE65 revealed
a delineation between injected areas showing overexpression of RPE65 and
untreated areas expressing endogenous RPE65 in all NHPs although RPE65
protein was reduced in areas where there was RPE damage (Figure S2.2).

Next we asked if similar FAF and SD-OCT changes would be observed after
administration of the now clinically available LuxturnaTM in patients. The fundus
autofluorescence characteristics of patients with biallelic RPE65 mutations and the
change after treatment with AAV2-hRPE65 has not been extensively studied,
partially due to the fact that the SW-FAF signal is frequently weak to absent in this
condition as a result of the profound abnormality in the retinoid cycle (Katz and
Redmond, 2001; Lorenz et al., 2004; Lorenz et al., 2008). A patient with RPE65LCA was imaged using NIR-FAF and SD-OCT (HRA+Spectralis system,
Heidelberg Engineering) before and after administration of LuxturnaTM following
the same methodology as in the NHPs experiments (Figure 2.5). The subretinal
injections covered the entire central retina and the area of photoreceptor
preservation on SD-OCT retinal thickness topography maps (Figure 2.5A). Before
treatment there was a residual central oval island of relatively preserved NIR-FAF
signal that corresponded with the detectable RPE and ONL on SD-OCT (Figure
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2.5B). Repeat retinal imaging a month after the subretinal injections show nearly
identical images on NIR-FAF as well as on SD-OCT compared to baseline
suggesting the changes observed in the outer retina and RPE in NHPs after
administration of AAV2-hRPE65v2 are specific to the NHPs.

Defining the immune response on same eye readministration of AAV2hRPE65v2
Baseline serum neutralizing antibody (Nab) titers to AAV2 ranged from negligible
to high (Figure 2.6A), likely due to prior wild-type AAV2 exposure, which closely
resembles the variation in AAV2 antibody titers observed in human sera (Amado
et al., 2010; Chirmule et al., 1999; Calcedo and Wilson, 2016). As expected, none
of the NHPs had a detectable antibody titer to the RPE65 protein at baseline as
measured by enzyme-linked immunosorbent assay (ELISA). There were no
changes in antibodies to RPE65 protein after the injections (data not shown). After
the first bilateral subretinal injections, serum AAV2 NAb titers rose significantly in
two of the three NHPs. One of them, BF54F, had had a negligible titer at baseline.
In the other, 10C015, titers rose from <1:100 to peak close to <1:1000, but dropped
back down to baseline levels after the second injection. There were no observable
changes in the remaining NHP (Figure 2.6A). Baseline NAb concentrations to
AAV2 in the anterior chambers (AC) averaged between the left and right eyes,
were <1:10 in all three NHPs. Upon termination of the study, the AAV2 AC NAb
titers had risen to <1:100 in BF54F and 1:1,000 in 11D086. There was no
observable change in AAV2 antibody titers in the AC of 10C015 (Figure 2.6B).
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To assess T cell responses to the AAV2 capsid and RPE65 protein, we measured
interferon-gamma

(IFN-g)

cytokine

secretion

using

an

enzyme-linked

immunosorbent spot (ELISpot) assay on PBMCs collected at baseline prior to each
subretinal injection and at 2-week intervals following the second injection (Figure
2.1). Cells were stimulated with AAV2 empty capsid particles and RPE65 peptide
pools. Animal BF54F did not have a T cell response at baseline, but developed a
T cell response to the AAV2 capsid four weeks after the second administration of
AAV2-hRPE65v2 (Figure 2.7). This response decreased by the 6 week postreadministration timepoint. There was no significant T cell response to any of the
RPE65 peptide pools. Thus, same eye subretinal readministration of AAV2hRPE65v2 in unaffected NHPs resulted in both a humoral immune response to the
AAV2 capsid and a cell-mediated immune response in one animal, BF54F, as well
as a transient increase in serum antibodies in another animal (10C015).
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Discussion
The extraordinarily successful treatment of a childhood blindness (RPE65associated IRD) by gene augmentation with AAV2-hRPE65v2 has reenergized the
entire gene therapy field with the approval by the FDA of this treatment
(LuxturnaTM, Spark Therapeutics Inc., Philadelphia, PA, USA) for use in the clinic
in December of 2017. A Phase 3 trial that supported this decision demonstrated
robust and early improvements in retinal function in the majority of subjects (93%)
after a single, localized, subretinal injection of the therapeutic agent in each eye.
Sensitivity to light post-treatment increased on average by about a hundred fold,
supporting enlarged visual fields that permitted better obstacle avoidance and
overall improved quality of life (Russell et al., 2017). The trial further confirmed the
treatment’s safety. Complications included temporarily elevated intraocular
pressure, cataracts, retinal tear (10% of participants), macular hole (one eye of
one participant) and decreased foveal function (albeit improved extrafoveal light
sensitivity, one participant), all of which have been attributed to the intraocular
surgical procedure needed for the delivery of the recombinant virus to the
subretinal space, including a vitrectomy, the creation of a localized retinal
detachment, and then a fluid-air exchange within the vitreous cavity. Safe and
successful treatment of the contralateral eye of previously treated (uniocularly)
RPE65 patients was subsequently demonstrated (Bennett et al., 2016; Bennett et
al., 2012; Amado et al., 2010). Readministration of a gene therapy vector to a
previously treated eye or region within a tissue such as the retina, however, is an
unavoidable subject that has not been explored experimentally in the retina and
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which has only been limitedly addressed elsewhere (Perrin et al., 2019; Peden et
al., 2009). Scenarios where same eye readministration may be indicated include
the treatment of untreated regions to further expand vision, the treatment of
regions that may be purposely spared during a staged treatment protocol where
the frailty of the degenerated retina is tested in visually non-sensitive areas before
extending the treatment to include critical areas for vision, such as the central
retina, and as a treatment booster should a decline in efficacy be detected over
time.

In the present study we used in vivo multimodal retinal imaging, measures of
cellular and humoral immunity and histopathology to explore the consequences of
ipsilateral readministration of rAAV2-hRPE65v2 in NHPs. The treatment in patients
leaves minimal visible evidence just a few days or weeks after the injections. In
contrast, the administration of rAAV2-hRPE65v2 to NHPs produces pigmentary
changes within the blebs visible by fundus exam as early as three days postinjection, which can be used to precisely locate a second subretinal injection in
relationship to a previous one. In one animal (two eyes), a readministration of the
treatment was at a site distant from the first injection to exclude mechanical
(surgery-related) effects on the initially injected retina; in the other two animals, the
treatment was delivered so that there was a partial or total overlap between the
first and second injections (Takahashi et al., 2018; Bennett et al., 1999). The
experiments demonstrated that ipsilateral readministration to the NHP retina was
safe from an immunologic standpoint, even when readministration location
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coincided nearly exactly with the initially treated retinal area. Repeat injections
were well-tolerated even though the initial injection had resulted in an increase in
systemic and local neutralizing antibodies to the AAV2 capsid in all of the animals.
There were no clinical signs of inflammation and the ocular media remained clear
even though the animals had not been treated with systemic steroids.

In vivo multimodal retinal imaging allows a view at the microscopic detail of large
expanses of retina overcoming potential under-sampling and/or simplifying the
sampling process that would be required with histology. The imaging protocol used
in this work, which resembles a protocol used in the human retinal degeneration
clinic for over a decade, was designed so that close registration could be achieved
between images obtained after each of the injections allowing precise qualitative
and quantitative comparisons (Aleman et al., 2007). Furthermore, structures in the
outer retina, such as the photoreceptor outer segments, as well as potential
changes in the content of certain fluorophores within the RPE, such as lipofuscin
and melanin, can be readily assessed in vivo, details that can only be viewed with
histology after laborious tissue processing. SD-OCT after the initial administration
or readministration of rAAV2-hRPE65v2 revealed no obvious signs of intraocular
inflammation such as hyperreflective images within the vitreous or the retina that
would suggest migration of inflammatory cells or the presence of overt infiltrates.
There were, however, examples of subretinal images that may correspond to
accumulation of subretinal material, including inflammatory cells, migrated RPE
cells, and/or shed unphagocytized outer segments. Of interest, animal 10C015,
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that showed a humoral (but not cellular) immune response, had such images. The
most consistent and dramatic change on imaging was the presence of round areas
of depigmentation within the blebs (first and second injections) on en-face imaging
that corresponded with loss of the IZ signal suggesting loss of the photoreceptor
outer segment tip and demelanization of the RPE. Readministration of the vector
in the overlapping blebs led to overlapping additional depigmentation but did not
lead to worsening of the existing changes. The photoreceptor nuclear layer and
the inner retina had a normal appearance suggesting the abnormalities were
compartmentalized to the subretinal space exposed to the treatment. Regions of
RPE loss were negative for RPE65 protein by immunohistochemistry, although
neighboring regions with intact RPE showed robust presence of RPE65. RPE
abnormalities of this magnitude have not been reported in humans after subretinal
gene therapy for RPE65 deficiency although versions of this appearance are
known to occur after persistent submacular retinal detachments (Simonett et al.,
2016). Of note, a patient treated in this study with this vector and imaged using
nearly identical protocol failed to demonstrate demelanization or loss of the POS,
which suggests the abnormalities are NHP-specific. Dose-dependent outer retinal
changes with demelanization of the RPE have been reported after the
administration of a different vector construct in NHPs suggesting that the
abnormalities may be vector-independent and perhaps the consequence of low
grade, immune-mediated responses within the subretinal space triggered by
exposure of human proteins that may not be detected by the immune assays used
in this work or by routine histopathology (Takahashi et al., 2018; Nork, 2012;
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Aleman et al., 2017). The rapid onset of the pigmentary changes can be noted on
fundus examination as early as 72 hours post-treatment in NHP. Causes of such
an acute damage to the POS and RPE include susceptibility to mechanical trauma,
delayed (subclinical) reattachment of the retina, choriocapillaris hypoperfusion as
the result of transiently elevated subretinal pressures, as well as changes in the
osmolarity within the subretinal space (Takahashi et al., 2018; Simonett et al.,
2016; Penha et al., 2008). The predilection for POS and apical RPE damage with
preservation of the rest of the photoreceptor cell integrity (i.e. the ONL) stands
against a significant ischemic insult expected to cause photoreceptor and RPE
cellular loss (Ancona-Lezama et al., 2019; Werner et al., 2017). The lack of
restoration of the POS and apical RPE anatomy with time argues against
mechanical or osmotic insults, or delayed retinal reattachment to the RPE
(reattachment was confirmed clinically by 72 hours, by OCT at one month postinjection), as the expectation is that of recovery, unless the abnormalities result
from irreversible structural damage (Takahashi et al., 2018; Simonett et al., 2016;
Saleh et al., 2014; Guerin et al., 1989; dell’Omo et al., 2015; Guerin et al., 1993).

Histopathology of the ipsilateral readministered injections at the termination of the
study showed a pattern indistinguishable from earlier descriptions following a onetime subretinal administration of gene therapy products in NHPs (Jacob son et al.,
2006; Nork, 2012; Jacobson et al., 2006; Reichel et al., 2017; Peters et al., 2019).
Histopathologic changes included RPE hyperplasia, focal RPE loss, and
proliferation. Of note, the immunologic profile was not predictive of the histological
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abnormalities and did not relate to the overlap between the initial and
readministered treatment. For example, the most severe inflammation was
observed in the retinas of the animal in which the blebs did not overlap (10C015).
Specifically, there were dislodged RPE cells which were hypertrophic and showed
signs of RPE proliferation. In some areas, the border between the RPE and the
underlying Bruch’s membrane was blurred, which corresponded with retinal
imaging findings suggestive of RPE loss and proliferation discussed before. This
animal, had not had evidence of either a cell-mediated immune response to AAV2
at baseline although it did have baseline humoral anti-AAV2 NAbs (reciprocal
dilution of >1:10). The inflammation was localized to small, focal regions in the
choroid underlying the original bleb sites and did not spill into the overlying retina
suggesting a compartmentalized response. There was no evidence of cellular
infiltrate that might have been directed at the recombinant AAV or the RPE65
transgene product, except for within isolated pockets in the choroid despite prior
exposure to AAV2 based on baseline serum titers. On the other hand, the animal
with total overlap between the first and second injection showed the least structural
change, whereas the animal with the highest baseline NAb titer directed against
AAV2 (11D086) showed the mildest histologic changes after readministration (mild
RPE pigment migration and focal RPE disorganization, one mild focal site of
choroidal inflammation). Only one animal that had low baseline NAb titers to AAV2
(BF54F) developed a cell-mediated immune responses to AAV2 four weeks after
the second administration – around the time when an immune response would be
expected to be close to maximal. Again, the structural change after
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readministration was indistinguishable from the other two animals. The findings
suggest a role for mechanical variables which were uncontrolled in these
experiments. Efforts are underway to de-risk the subretinal injections in patients
with the use of mechanical devices that deliver precise volumes at prescribed
hydrostatic pressures as well as with the use of intraoperative SD-OCT systems
that allow real time view of the microscopic retinal structure during the surgical
interventions (Fischer et al., 2016; Xue et al., 2017). Experiments in NHPs
following similar precautions are needed to narrow down the possible causes
(Takahashi et al., 2018).

The findings are relevant for the interpretation of experiments where human
proteins are expressed by gene therapy in NHP retinas in preclinical assays of
safety as well as for gene therapy treatments that are being conducted in patients.
Although the exact mechanism(s) that lead to these abnormalities are yet to be
fully elucidated, limited POS and RPE changes may be expected in similar
experiments and may not necessarily indicate an unsafe treatment for patients
(Aleman et al., 2017; Takahashi et al., 2018; Nork, 2012; Reichel et al., 2017;
Peters et al., 2019; Ochakovski et al., 2017; Seitz et al., 2017). Monitoring of the
health of the injected retina in patients is thus warranted particularly when the
target outcome of the retinal gene therapy procedure lies distant to the treated
regions, such as in applications where gene therapy is used to produce secretable
proteins, as loss of a protein expressing RPE will lead to the loss of the gene
product and treatment efficacy (Aleman et al., 2017; Rakoczy et al., 2015). On the
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other hand, comparatively mild but potentially visually significant changes in the
outer retina reported after subretinal gene therapies and in presumed inflammatory
diseases of the outer retina may represent versions of the abnormalities observed
in NHPs (Aleman et al., 2017; Dimopoulos et al., 2018; Hauswirth et al., 2008;
Aleman et al., 2017). The findings underscore the need for a better understanding
of the pathophysiology of the outer retinal changes after subretinal delivery of gene
therapies in NHPs and in patients to improve the safety and outcomes of these
treatments.

As noted earlier, responses to the subretinal injection in NHPs treated with AAV2hRPE65v2 appear to differ in important ways from those in humans treated with
LuxturnaTM. Subretinal injection in NHPs results in outer retinal and RPE changes
at the border and in the center of injection blebs (Figure S2.4). Such findings are
absent in humans treated with LuxturnaTM, or for that matter, with another AAV2
vector in which the CHM cDNA replaces RPE65 (AAV2.hCHM) (Acland et al.,
2001; Aleman, 2019). Could this be explained by differences in the surgical
procedures and peri-operative medications used in human subretinal surgery
versus the NHP studies reported here? Human subretinal injections are carried out
using a three port pars plana vitrectomy (without anterior chamber paracentesis)
followed by a fluid-air exchange. The NHP injection procedure is modified such
that there is no vitrectomy and only one port that is used to introduce the injection
cannula. The appearances of the treated regions of the retina in NHPs are
reminiscent of the pattern described by Xue et al. relating to the contour map of a
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bleb and so may relate to the temporal difference in reattachment in the human
(who receives an air-fluid exchange after the injection) versus the NHP (which
does not) (2017). In fact, circular, ring-like autofluorescent patterns documented in
these NHP experiments may represent stages of bleb reabsorption (for example,
Fig. 2.4, animal 11D086). The goals of the NHP surgery were to reduce anesthesia
time and to consider the surgical anatomy of these smaller animals. Human
subretinal injections delivering AAV2-hRPE65v2 in Phase I-III trials or after FDA
approval, delivering LuxturnaTM, include peri-operative treatment with prednisone,
whereas no systemic steroids were used in the NHP studies, which were purposely
omitted to avoid interference with the development of an immune response and
inflammation after ipsilateral readministration of the vector. Thus, the results from
this preclinical study in NHPs likely reflect what would be the “worst case” scenario
of ipsilateral readministration in humans.

In summary, the results support the overall safety of the ipsilateral readministration
of AAV2-hRPE65v2 (LuxternaTM). Localized structural abnormalities confined to
the outer retina and RPE after readministration of the treatment in NHPs do not
differ from those observed after single or contralateral administration of this
therapy. The structural changes observed after administration of AAV2-hRPE65v2
(LuxternaTM) in NHPs contrast from the unchanged appearance of the human
retina exposed to the same vectors, suggesting there may be local immunologic
responses in NHPs retinas exposed to human proteins that escape detection with
current assays, and/or differences between human and NHP in the response to
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these treatments. Documentation of the early time-course of the reabsorption of
the subretinal fluid immediately following single injections in NHPs, the use of
control vehicles without viral capsids, the evaluation of outcomes in NHPs with and
without immunosuppression, as well as the use of more locally sensitive
immunologic assays are needed to narrow down the alternatives.
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Methods
Animals, study design and ocular surgery
The study was conceived as a prospective observational study. Included were
three 7-8 years of age NHPs, two cynomolgus and one rhesus macaque primate.
After a baseline evaluation (see below) each animal received subretinal injections
of the study agent in each eye followed two months later by readministration of the
same agent to each eye (Figure 2.1). The subretinal injection procedure was
carried out using sterile instrumentation, surgical fields, injectable and topical
medications. The subretinal injections were administered without a previous
vitrectomy and were performed under direct visualization through an operating
microscope after an anterior chamber paracentesis following procedures detailed
elsewhere (Amado et al., 2010). In brief, a needle was inserted through a trocar,
introduced by sclerotomy, at the 2 or 10 o’clock position which was then advanced
through the vitreous to penetrate the retina in the posterior pole. Under microscopic
control, 100-200 μL of the agent [resulting in doses of 1.0-2.0 E11 vector genomes
(vg)] was injected into the subretinal space, thereby raising a dome-shaped retinal
detachment (bleb). The solution was not drained, but was resorbed within a few
hours by the retina. The sclerotomy site was sutured with absorbable suture. After
each procedure, a subconjunctival injection of 15 mg of Kenalog solution (40
mg/mL) was delivered and the ocular surface was dressed with PredG
(prednisolone acetate-gentamicin, 0.3%/0.6%; Allergan) ointment. Other than that,
no immunosuppression was administered. Ophthalmoscopic examinations were
carried out prior to and immediately following subretinal injection, post-operative
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day 3 for each injection, and prior to euthanasia (Figure 2.1). Venous blood was
collected at baseline before the subretinal injections, at two week intervals
following the readministration and at termination of the study. Peripheral blood
monocytes (PBMCs) and sera were isolated from the venous blood samples. The
PBMCs were purified and stored in vapor phase liquid nitrogen and sera were
frozen at -80°C until testing. Aqueous humor samples to measure AAV-capsid
specific antibodies were obtained by anterior chamber paracentesis (ACP) at
scheduled intervals (Figure 2.1). ACPs were performed in a sterile manner using
a tuberculin syringe attached to a 30-gauge hypodermic needle; a maximum of up
to 100 µL of aqueous fluid was collected. At the termination of the study animals
were

euthanized

and

samples

collected

for

immune

assays,

immunohistochemistry and histopathology (Figure 2.1). The studies were in
compliance with local and federal guidelines and were carried out under an
Institutional Review Board approved protocol (The Children’s Hospital of
Philadelphia, IACUC protocol 1061) and were in accordance with the ARVO
Statement for the Use of Animals in Ophthalmic and Vision Research (Association
for Research in Vision and Ophthalmology, Rockville, MD).

Study agent
AAV2-hRPE65v2 contains hRPE65 cDNA under control of a constitutive promoter
(a hybrid chicken b-actin promoter with a cytomegalovirus enhancer) and a long
stuffer sequence designed to prevent reverse packaging (Bennicelli et al., 2008).
This is the same plasmid that was used to generate the reagent used in Phase 1,
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Follow-on, and Phase 3 clinical trials for RPE65 deficiency at The Children’s
Hospital of Philadelphia (CHOP) and the University of Iowa as well as the now
commercially

available

Luxturna™

(voretigene

neparvovec-rzyl,

Spark

Therapeutics Inc., PA, USA) (Russell et al., 2017; Maguire et al., 2008; Bennett et
al., 2016; Bennett et al., 2012; Maguire et al., 2009). The rAAV was manufactured
by the Research Vector Core at the Center for Advanced Retinal and Ocular
Therapeutics (CAROT) at the University of Pennsylvania Perelman School of
Medicine. The virus was manufactured after triple transfection of HEK293 cells and
was isolated and purified by microfluidization, filtration, cation exchange
chromatography (POROS 50HS; HE Healthcare, Piscataway, NJ), density
gradient ultracentrifugation and diafiltration in phosphate-buffered saline (PBS).
This combination provides highly purified, transgene cassette-containing AAV
particles and efficiently removes empty capsids and residual cesium chloride. The
purified virus, along with 0.001% Pluronic F-68 (PF68; BASF, Ludwigshafen,
Germany), was then passed through a 0.22-μm filter and stored frozen (–80oC) in
sterile tubes until use. Quality control procedures included sodium dodecyl sulfatepolyacrylamide gel electrophoresis and silver staining (for vector purity), real-time
quantitative polymerase chain reaction (to assess vector genome concentration),
osmolality, pH, and endotoxin testing.

In-vivo Retinal imaging
Retinal imaging was performed in fully anesthetized animals. A heating pad
maintained body temperature during the experiments. Vital signs were monitored
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periodically with a pulse oximeter and rectal thermometer. At the completion of
procedures animals were monitored closely through recovery. Pupils were dilated
with topical tropicamide (1%) and phenylephrine (2%). Eyes were kept opened
with an eye speculum inserted after topical anesthesia with proparacaine-HCL
(1%). Corneal lubrication and clarity was ensured by frequent instillation of
preservative free artificial. Retinal imaging was performed 1.5 months after the first
post-injection and 1 month after the readministration (Figure 2.1). En-face retinal
imaging was performed with near infrared (NIR, 790 nm) reflectance (REF) and
fundus autofluorescence (FAF) with NIR (820 nm) and short-wavelength (SW, 488
nm)

excitation

lights

using

a

commercially

available

scanning

laser

ophthalmoscope camera integrated with a spectral domain optical coherence
tomography (SD-OCT) system (Spectralis, Heidelberg Engineering, Carlsbad,
CA). Overlapping en-face imaging fields were collected with 30° and 55° lenses
extending into the midperiphery to cover as much as possible the injected regions.
Color fundus photography was performed with a wide-angle contact lens system
(RetCam3 instrument, Natus Medical Inc, Pleasanton, CA). SD-OCT scanning was
performed with 9 mm-long horizontal and vertical cross-sections through the fovea
and overlapping 30° x 25° mm raster scans extending into the near midperiphery.
Histological retinal laminae were quantified with the built-in automatic
segmentation of the Spectralis system, supervised to ensure correct identification
of the different laminar boundaries by visual inspection and with the use of
longitudinal reflectivity profiles (LRPs) extracted with available analysis software
(ImageJ; http://imagej.nih.gov/ij/; provided in the public domain by the National
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Institutes of Health, Bethesda, MD, USA). Total retinal thickness topography maps
were generated, which in conjunction with en-face imaging (NIR-REF and NIRFAF) were used to visualize the treated regions as areas of interest (ROI) where
a more focused analysis of the segmentation took place. Segmentation
parameters examined within AOI included: (1) total retinal thickness, defined as
the distance between the internal limiting membrane (ILM) and the basal side of
the retinal pigmented epithelium signal (RPE) at the level of the Bruch’s membrane
(BM); (2) Inner retinal thickness, defined as the distance between the ILM and the
outer plexiform layer; (3) Outer nuclear layer (ONL) thickness, defined as the
distance between the outer plexiform layer (OPL) and the external limiting
membrane (ELM); (4) Ellipsoid zone (EZ) band to the RPE/BM, defined as the
distance between these two bands on SD-OCT (Aleman et al., 2007; 2016, 2017).
Smaller regions within the AOI that co-registered perfectly as judged by coregistration of vascular landmarks before and after treatment were similarly scaled,
rotated and comparisons made between pre- and post-injection parameters.

Necropsy, Histopathology, and Immunohistochemistry
At the conclusion of the studies animals were euthanized, anterior chamber fluid
and vitreous samples collected, and eyes enucleated. The globes were fixed 24
hrs in 4% paraformaldehyde in phosphate-buffered saline (PBS) before OCT
embedding and cryosectioning. The posterior pole was isolated. Retina and
underlying RPE/choroid were cryoprotected in 30% sucrose in PBS and frozen.
Cryosections were made at 12 μm and designated sections were stained with 4′,657

diamidino-2-phenylindole (DAPI) or processed for immunohistochemistry for
RPE65.

Immunohistochemistry was carried out using a rabbit anti-mouse RPE65 (Novus
Biologicals, Centennial, CO) and an HRP-conjugated anti-mouse secondary
antibody (Amersham, Little Chalfont, United Kingdom) prior to DAB staining with
kit (Abcam, Cambridge, MA) or stained with hematoxylin and eosin (H&E). Slides
were evaluated in a masked fashion by a board-certified ocular pathologist (V.
Lee).

ELISpot assays
IFN-g assay on PBMCs were performed as previously described (Amado et al.,
2010). Response to an antigen was considered positive when the number of spotforming units (SFU) per 200,000 PBMCs was higher than 50 SFUs per 200,000
PBMCs and three or more times the SFU per 200,000 PBMCs measured for the
medium negative control. Phorbol myristate acetate (PMA) was used at a final
concentration of 5 ng/mL with ionomycin at 2mM as a positive stimulant to ensure
an equivalent number of functional T cells per well. For the experimental reagents,
RPE65 peptide libraries were generated by Mimotopes (Minneapolis, MN) and
consisted of 105 overlapping 15 mers combined in three pools (1-35, 36-70, and
71-105). Purified empty AAV2 capsids were used to test cell-mediated responses
to the AAV capsid as previously described (Maguire et al., 2008). SEMs were

58

calculated as the SD of the readings divided by the square root of the number of
readings.

NAb assay and ELISA antibody to AAV2
NAb titer to AAV2 was determined as previously described with a β-galactosidase
assay (Bennett et al., 1999). The positive control was maximumal transduction of
AAV2-LacZ without the addition of serum to the sample while the negative control
contained buffer only. Human sera samples previously assayed to be positive for
antibodies to the AAV2 capsid were used as reagent controls (Amado et al., 2010).

ELISA for antibodies to RPE65
Antibody titer to RPE65 was determined with an ELISA by modification of
previously described methods (Bennicelli et al., 2008; Bennett et al., 2012; Amado
et al., 2010). The positive control was the PETLET rabbit anti-mouse RPE65
antibody (gift of Dr. Michael Redmond). The titer was defined as the reciprocal of
the highest sample dilution such that the mean optical density for the test antigen
was at least three times that for the control antigen and at least three times the
background level, determined from the buffer only negative control. Bovine serum
albumin (BSA) was used as a negative antigen control.
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Table 1. Summary of characteristics of animals used in the study retinal
Age is given for the first injection timepoint. vg, vector genomes. *Relative position of the
readministered (readmin.) subretinal bleb in relationship to the initial bleb that resulted from
the first injection.
Injection #1
Anima
l ID

Species

Age
Gend
[year
er
s]

Right Eye
Volu
me
[μL]

Injection #2

Left Eye

Dose Volu
[vg*10 me
11
]
[μL]

Right Eye

Dose Volu
[vg*10 me
11
]
[μL]

Left Eye

Dose Volu
[vg*10 me
11
]
[μL]

Readmi
n.
Bleb
Location
s*

Dose
[vg*10
11
]

Cynomol
gus
10C01
(Macaca
5
fascicular
is)

F

8

180

1.8

120

1.2

200

2.0

150

1.5

No
overlap

Rhesus
(Macaca
mulatta)

M

9

100

1.0

150

1.5

150

1.5

150

1.5

Partial
overlap

Cynomol
gus
11D08
(Macaca
6
fascicular
is)

F

7

180

1.8

120

1.2

200

2.0

200

2.0

Complet
e
overlap

BF54
F
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A

B

Figure 2.1. Experimental Design
(A) Timeline (in months) of injection procedures, sample collection, and in-life assays.
Baseline samples were collected on Day “0”, immediately prior to the first subretinal
injection. Similarly, samples were collected again immediately prior to the second
subretinal injection on Day 60. Blood samples were then collected every two weeks until
termination of the study. Bl, phlebotomy; AC, anterior chamber paracentesis; OCT, optical
coherence tomography; Vit, vitreous biopsy. (B) Cartoons depicting the location and extent
of the blebs created after the bilateral subretinal injections in each of the three animals for
the first (violet) and second (turquoise) administrations for each eye. Regions of overlap of
the two injections appear in blue.
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Figure 2.2. En-face retinal imaging and cross-sectional retinal microscopy obtained in
life for the right eye of each of the three animals that received bilateral
readministration of AAV2-hRPE65v2.
(A) Wide-angle color fundus photography of ocular fundus partially covering the injected
regions. (B) Wide-angle (55 deg) short-wavelength fundus autofluorescence (SW-FAF) of the
same regions obtained after the first and second injections of the vector. Scale bar is at the
bottom right. Superimposed thin green line is one of 62 horizontal raster SD-OCT scans use
to generate maps of the overall retinal thickness topography in (C). The 9 mm x 7 mm maps
straddle the boundary between injected and uninjected retina. Imaging was performed 1.5
months after each injection. Thickness values are plotted to a color scale (bottom right). Only
right eyes shown for clarity; left eyes are virtually identical copies of the right eye.
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Figure 2.3. In-life microscopic retinal structure and ex vivo histopathology.
(A) Magnified, 2.3-mm-long, SD-OCT segments (horizontal thick arrows in Fig. 2.2B) from a
location ~1.5 mm from the optic nerve edge extracted from raster scans used to map a 9 x 7
mm area of retina at ~100 mm intervals in (C). Images were obtained 1.5 months after the 1st
injection and 2nd injections of the vector. Selected cross-sections sample the retina from
uninjected to within the injected subretinal bleb that resulted from the first (overlaid horizontal
violet bars) and second (turquoise bars) injections. Overlapping injected retinas shown as
blue bars. Asterisks point to vascular landmarks used to ensure co-registration with en-face
SW-FAF images in (B), as well as to ensure the same region is evaluated on SD-OCT after
the 1st and 2nd injection. Neuronal nuclear (outer nuclear layer, ONL; inner nuclear layer, INL;
ganglion cell layer, GCL) and axonal (retinal nerve fiber layer, RNFL) layers are labelled.
Outer retinal sublaminae are numbered (1- external limiting membrane, ELM; 2- inner
segment ellipsoid region band (EZ); 3- interdigitation zone (IZ) between the tip of the POS
and the apical RPE; 4- RPE/BrM. (B) Representative hematoxylin and eosin sections. White
arrows point to hyperreflectivities superficial to the RPE on SD-OCT and hypertrophy and
migration of RPE cells on histology. Yellow arrows point to attenuation of the IZ signal on SDOCT and abnormal outer segments on histology. Only right eyes shown for clarity; left eyes
are virtually identical copies of the right eye. (C) Comparison of quantitative structural SDOCT parameters expressed as a fraction of the 2nd/1st injection time point values for injected
(‘blebs’) (red bars) and uninjected (green bars) retina, as well as ratios of values measured
inside/outside the blebs after the 1st (gray bars) and the 2nd (black bars) injections.
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Figure 2.4. Outer retinal changes evaluated by en-face and cross-sectional SD-OCT
retinal imaging.
En-face near infrared (NIR) reflectance (REF) and fundus autofluorescence (FAF) imaging
with NIR and short-wavelength (SW) excitation lights. Representative 2.3 mm magnified SDOCT cross-sections through the boundary (vertical dashed lines) of the injected blebs. Green
lines on en-faceI imaging denotes represent the location and orientation of the SD-OCT
scans. Nuclear layers and outer retinal sublaminae labeled in Fig. 2.3. Asterisks: denote
subretinal hyperreflective image that may correspond to deposits and/or fibrosis observed on
histology and hyper-FAF. Arrow: points to hyperreflectivities apical to a disrupted RPE/BrM
band that should correspond to RPE abnormalities described on histology. Circle: intraretinal
linear reflectivities reflecting intraretinal pigment migration and/or reactive gliosis/Muller cell
hypertrophy. Short arrow: retinotomy.
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Figure 2.5. Administration of AAV2-hRPE65v2 (LuxternaTM) to a patient with RPE65LCA.
Multimodal retinal imaging was performed as in the NHP experiments pre- and post-treatment.
(A) SD-OCT total thickness tomography (left) and NIR-FAF pre- vs one month after treatment.
Yellow contour denotes area with clearly detectable ONL (>10% or mean normal thickness)
covered by the subretinal injection or bleb. (B) SD-OCT, 6 mm-long cross-sections through
the fovea before and after treatment. Nuclear and outer sublaminae as in Fig. 3. Inset: NIRREF image with an overlaying arrow to show the position and orientation of the scans. T:
temporal; N: nasal retina. Scale bar bottom left.
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Figure 2.6. Neutralizing antibodies (NAbs) to AAV2 capsid in serum and anterior
chamber fluid at baseline and at various timepoints following the first subretinal
injection.
NAbs in serum (A) and average NAb titers calculated for both eyes in AC fluid and vitreous
samples (B) from baseline prior injection 1 (Week 0) through the end of the study. All NHPs
had high AAV2 NAb titers present in the vitreous of both eyes upon termination [Vitreous could
not be collected at baseline due to the invasiveness of the procedure].
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Figure 2.7. T cell responses directed against AAV2 capsid or the RPE65 protein as a
function of time after ipsilateral subretinal readministration of AAV2-hRPE65v2.
(A to E) IFN-g secretion by PBMCs after stimulation with the AAV2 capsid and RPE65 protein
as measured by an IFN-g ELISpot assay using peptide pools. PMA+ION, positive control.
Response to an antigen was considered positive when the number of spot-forming units (SFU)
per 200,000 PBMCs was higher than 50 SFUs (dotted line) per 200,000 PBMCs and three or
more times the SFU per 200,000 PBMCs measured for the medium control. Error bars indicate
SEM, calculated as the SD of the readings divided by the square root of the number of readings.
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Figure 2.8. Example of focal and rare histopathological findings.
Shown are hematoxylin and eosin-stained cryosections from the right retina of 11D086. (A)
There is a focal break in the RPE layer (arrow) coinciding with shortening of outer segments.
B) Fibrinoid scar (*) is present in the subretinal space; (C) focal collection of monocytes in the
choroid, extending towards subretinal space. The RPE is missing in this area. Inset shows a
higher magnification view of this area. GCL, ganglion cell layer; INL, inner nuclear layer; ONL,
outer nuclear layer; OS, outer segments; RPE, retinal pigmented epithelium.
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Figure 2.9. Representative RPE65 immunohistochemistry result after ipsilateral
subretinal readministration in a non-human primate (BF54F).
In (A) injection region #1, (B) overlapping injection region, and (C) on injection region #2. (B)
Arrowheads, dislodged RPE cells; arrow, atrophic retinal pigmented epithelium (RPE) cells;
ch, choroid.
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Figure 2.10. Example of contour map-like appearance effect documented by imaging with
a RetCam equipped with fluorescein filters after subretinal injection of AAV-EGFP in a
NHP.
Shown are hematoxylin and eosin-stained cryosections from the right retina of 11D086. (A)
There is a focal break in the RPE layer (arrow) coinciding with shortening of outer segments.
B) Fibrinoid scar (*) is present in the subretinal space; (C) focal collection of monocytes in the
choroid, extending towards subretinal space. The RPE is missing in this area. Inset shows a
higher magnification view of this area. GCL, ganglion cell layer; INL, inner nuclear layer; ONL,
outer nuclear layer; OS, outer segments; RPE, retinal pigmented epithelium.
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Abstract
AAV8BP2 is an in vivo selected capsid we have previously identified for targeting
bipolar cells with higher efficiency than other parental serotypes. However, there
is room for improvement as this capsid appears to be less potent than AAV8 when
compared in vitro in HEK293 cells and transduced very few bipolar cells even at
high doses in the NHP retina. We sought to engineer AAV8BP2 through rational
design to further improve upon its potency by mutating tyrosine residues within the
capsid DNA. We generated GFP reporter vectors under the control of a constitutive
promoter and encapsulated them in variant AAV8BP2 capsids containing
canonical tyrosine mutations, Y447F, Y733F, or Y447F and Y733F. Only the vector
containing the Y733F mutation outperformed the native AAV8BP2 in vitro and in
vivo. Additionally, we evaluated the cellular tropism of these new vectors and
observed increased transduction of photoreceptors in mice with the Y733F mutant
AAV8BP2 capsid as compared to AAV8BP2 and AAV8. These findings serve to
expand the capsid toolbox for photoreceptor targeting.
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Introduction
One of the major challenges to developing new retinal gene therapies is our ability
to effectively target specific cell types that are non-permissive to wtAAV while
avoiding the transduction of healthy tissues and cell populations. The specificity of
AAV as a gene transfer tool is one of its most favorable features because it reduces
the risk of systemically expressing genes and immunogenicity. Conversely, this
specificity requires the advent of new capsid serotypes that target cells of interest
to overcome disease phenotypes in cells that are all but impenetrable to AAVmediated gene therapy.

Luckily, several naturally occurring AAV serotypes that are able to transduce
different cell types in the retina with greater efficiency than AAV2 have been
recognized. However, efficient transduction can have different meanings
depending on the causative gene and natural history of the disease. As is the case
in the retina, sometimes we are able to transduce many cells with the same
serotype, including cells in which transgene expression might have negative
consequences. In this scenario, we can utilize cell-specific promoters to restrict
expression to just the cells of interest. In other scenarios, therapeutic protein levels
might require much more expression than we’re able to attain with any of the AAV
serotypes at our disposal, even if transduction of the target cell type is reasonable.
Additionally, it is favorable to use the lowest vector dosage to reach therapeutic
levels to decrease the likelihood of an immune reaction.
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In order to create more potent vectors, we must first understand what limits AAV
vector transduction. Firstly, AAV enters cells by binding to specific surface
receptors and eventually undergoing endocytosis. The absence or low abundance
of required cellular surface receptors for viral attachment and internalization is the
first roadblock. If the viral vector does manage to get inside the cell, it must then
escape the endosome. Inefficient endosomal escape leads to lysosomal
degradation – the second roadblock. Once the AAV is in the cytoplasm it must then
be trafficked to the nucleus where it uncoats to release its genome. Here, the
single-stranded genome must convert to double-stranded DNA (dsDNA) to
become a template for transcription. Slow conversion of ssDNA to dsDNA is the
primary cause for delayed expression profile due to the rapid degradation of what
the cell believes is a DNA damage signal and is the final roadblock (Hauck et al.,
2004). The cumulative efficiency with which AAV can successfully execute each
of these individual steps determines the overall transduction efficiency.

Scientists have developed several strategies to help us expand our AAV toolbox
to overcome these rate limiting steps. As mentioned previously, several naturally
occurring serotypes have been discovered in rhesus monkeys that are now used
as vectors for potential human gene therapies and natural variants continue to be
discovered. Additionally, hybridized serotypes have been created in the laboratory
through a variety of methods. The first is transcapsidation, which packages the
genome containing ITRs from one serotype in the capsid of a different serotype.
Currently, all the vectors in clinical use are hybrids of AAV2 ITRs and other AAV
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capsids. The second method is adsorption modification where foreign peptides that
can be recognized by known cell surface receptors are adsorbed on the capsid
surface. Third is the use of a mixture of unmodified capsid proteins from two
different serotypes, known as mosaic capsids. This differs from chimeric capsids
in which foreign peptide sequences are fused at either the N- or C-terminus of viral
protein or as an insertion into a VP sequence of the Cap gene (Choi et al., 2006).

One question that researchers kept asking was whether it was possible to create
an environment that drives AAV evolution towards specific tropisms and/or
improved production efficiency? What if AAV was forced to adapt to certain set
conditions in the lab to create new AAV serotypes that are better than those that
have evolved in nature? This approach is known as directed evolution. First, the
entire Cap gene is subjected to mutagenesis and recombination to create a
plasmid library of capsid mutants. This library can then be screened for infectivity
in vitro as well as cellular tropism in vivo to determine which mutants best serve
your need. These choice capsid mutants are then subjected to additional rounds
of mutagenesis and selection to enrich the pool of “designer” rAAV capsids
(Schaffer and Maheshri, 2004; Bartel et al., 2012).

AAV8BP2 was created through this process using mutagenesis of AAV8 and in
vivo selection to target bipolar cells with higher efficiency than other AAV serotypes
at our disposal (Cronin et al., 2014). Much of the early-stage processing of visual
inputs occurs within retinal bipolar cells and the failure of available AAV vectors to
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transduce these cells has impacted both basic research and development of IRD
therapies. In particular, a therapeutic strategy for advanced forms of blindness in
which photoreceptor degeneration is extensive involves using optogenetic
molecules to render ON-bipolar cells light-sensitive (Lagali et al., 2008; Gaub et
al., 2014; Macé et al., 2015; Scalabrino et al., 2015). Currently, our ability to
achieve therapeutic levels of gene expression is the limiting factor for this
approach. AAV8BP2 has shown exciting promise for bipolar cell transduction in
mice, but as demonstrated by Ramachandran et al, the tropism of the vector differs
when administered subretinally or intravitreally in NHPs (2017). The differences in
species-specific vector tropism is one of the downfalls of in vivo directed evolution.
An AAV serotype used for gene therapy in mice may result in phenotypic
correction, but this outcome isn’t always replicated in large animal or human
retinas due to the inherent differences in structure. This phenomenon comes into
play particularly when an AAV capsid is modified through in vivo selection in mice.

The rational mutagenesis of specific surface-exposed amino acid residues on the
AAV capsid, including tyrosine (Y), serine (S), threonine (T), and lysine (K), has
been shown to achieve high-efficiency transduction in a wide range of retinal cells
at lower vector dosages (Petrs-Silva et al., 2009). More specifically, tyrosine
mutations of AAV8, the parent serotype of AAV8BP2, improved the expression
profile of reporter vectors in vitro. This occurs as a result of reduced tyrosine
phosphorylation, which acts as a signal for AAV vector ubiquitination and
subsequent targeting for degradation by cellular proteasomes (Zhong et al., 2007).
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We wanted to evaluate the intraocular transduction characteristics of AAV8BP2
vectors containing these same point mutations in surface-exposed capsid tyrosine
residues. We hypothesized that mutating the highly conserved capsid tyrosine
residues could improve the transduction efficiency of parental serotype AAV8BP2.
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Results
Generation of eGFP-reporter vectors containing canonical tyrosine
mutations
The AAV8BP2 capsid plasmid, which is derived from the AAV8 parental serotype
and contains a small stretch of mutated DNA (Fig 3.1A), was used alongside InFusion cloning primers to perform mutagenesis on one or both tyrosine residues
to produce a base substitution at amino acid sites 447 and 733 to code instead for
phenylalanine. Tyrosine is a polar, uncharged amino acid that possesses a
hyrdroxyl group in an aromomatic ring, making it a derivative of phenol (Fig 3.1B).
This hydroxyl group is subjected to phosphorylation posttranslation modification.
Although phosphorylation doesn’t always act as a targeting signal to send proteins
to

the

proteasomal

degradation

pathway,

protein

phosphorylation

and

ubiquitination cross talk at many levels (Hunter, 1997). E3 ubiquitin ligase
specifically stimulates the ubiquitination of phosphotyrosine-containing proteins
(Gao and Karin, 2005). Mutating these tyrosine residues to phenylalanine, a
nonpolar amino acid, facilitates viral nuclear transport by limiting proteasomemediated degradation (Petrs-Silva et al., 2009). Furthermore, the hydrophobic
aromatic side chain of both tyrosine and phenylalanine should preserve the AAV
capsid structure. The Y447F and Y733F mutations were confirmed by sequencing
(Fig. 3.1C). The recombinant AAV vectors contained an expression cassette with
cDNA encoding enhanced green fluorescent protein (eGFP) under the control of a
strong, constitutive CAG promoter.
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Determination of in vitro and in vivo transduction efficiency of tyrosinemutant AAV8BP2 vectors
The transduction efficiency of each of the mutant vectors was first assessed by
transducing HEK293 cells and performing RT-qPCR to determine the relative
amount of eGFP transcription. AAV8 was used as a common reference for all
serotypes. AAV8BP2(Y447F), AAV8BP2(Y733F), and AAV8BP2(Y447F,Y733F)
outperformed AAV8BP2 (Fig 3.2). AAB8BP2(Y733F) showed a 2-fold increase in
comparison to the parental serotype. This was equivalent to the fold change
observed with AAV8 transduction. While this data is informative for determining
overall transduction efficiency in a mammalian cell system, it was important to
additionally test these vectors in a more physiologically relevant setting.

One microliter (μL) of each AAV8BP2 single tyrosine-mutant containing 1E10 vg
copies was injected either subretinally or intravitreally into contralateral eyes of
adult C57BL/6 mice. eGFP expression was analyzed by fluorescent fundoscopy
four weeks post-injection. We observed robust eGFP expression in all mice
injected subretinally, but no eGFP expression in any of the mice injected
intravitreally (Fig 3.3). However, upon cryosectioning and immunohistochemistry,
these retinas showed severe thinning of the ONL. This was observed with all the
tested vectors, suggesting that this degeneration was not due to vector toxicity, but
rather an external factor, such as light-induced damage (Fig not shown).
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Given the amount of expression achieved with all vectors injected subretinally, we
performed this experiment a second time with 5E8 vg copies in order to better
elucidate differences in potency between the vectors. Fundoscopy performed four
weeks post-injection revealed eGFP expression that was more localized to the site
of the injection (Fig 3.4A). Similar GFP intensity was observed between AAV8BP2
and AAV8BP2(Y733F) with AAV8BP2(Y447F) exhibiting the least amount of all
the vectors (Fig 3.4B). Upon termination of the study, RT-qPCR was used to
analyze the relative amounts of eGFP expression between each of the vectors.
AAV8BP2 and each of the single tyrosine-mutant vectors displayed greater fold
change in eGFP expression than AAV8 (Fig 3.4C). However, AAV8BP2(Y733F)
had the greatest fold change, correlating with the in vitro transduction results.
Interestingly, AAV8BP2(Y447F) showed less transgene expression than
AAV8BP2.

In an effort to determine if we could achieve a wider distribution of transduced cells
within the murine retina, we tested these vectors in vivo again, this time using 1E9
vg

copies

per

vector

and

including

the

double

tyrosine-mutant

AAV8BP2(Y447F,Y733F) in the experiment. Fluorescent fundoscopy performed
four weeks after the subretinal injections revealed widespread eGFP expression
with all vectors (Fig 3.5A). (eGFP intensity, RT-qPCR and WB in progress; Fig
3.5B, 3.5C, and 3.5D).

Evaluation of retinal cellular tropisms of tyrosine-mutant AAV8BP2 vectors
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Immunohistochemical analysis to assess the cellular tropism of the vectors at the
lower dose indicated efficient RPE cell transduction with all sub-serotypes (Fig
3.6A). AAV8BP2(Y733F) also showed eGFP expression colocalizing with cone
photoreceptor marker cone arrestin (CAR) at the axon termini and a very small
amount of in the cell bodies. This observation is likely due to the low vector dosage
used, so we evaluated the retinas that received a higher dose of rAAV in order to
ascertain any differences in vector tropism (Fig 3.6B).
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Discussion
The efficiency of rAAV transduction is dependent on multiple virus-host cell
interactions mediated first and foremost by the AAV capsid. It holds sway over both
the kinetics of transduction and cellular tropism. The ability to modulate the capsid
to improve upon or influence these properties is essential in moving the field of
gene therapy forward. Combined with engineering of the expression cassette to
use cell-specific promoters, the specificity and safety of AAV is more pronounced
than ever. In the retina, the transduction efficiency of different AAV serotypes has
been well characterized (Surace and Auricchio, 2008; Hellström et al., 2009).
Several of the serotypes specifically target RPE cells, photoreceptors, or both
when injected subretinally (Yang et al., 2002; Weber et al., 2003; Allocca et al.,
2007; Lebherz et al. 2008). However, fewer serotypes transduce cells of the inner
retina, including bipolar and ganglion cells, let alone efficiently. This has hindered
the development of gene therapies to treat IRDs that manifest in these cells and
advanced forms of retinal degeneration in which the lack of remaining
photoreceptors requires novel treatment strategies.

For this reason, we created AAV8BP2 through in vivo directed evolution. In this
study, we aimed to further improve upon the transduction efficiency of this vector
through rational mutagenesis of the cell surface-exposed tyrosine residues. Upon
subretinal and intravitreal injection in unaffected mice, we observed robust reporter
plasmid expression with subretinal administration, but no expression with
intravitreal administration. This finding comes in contrast to work done by Petrs84

Silva et al., in which they documented enhanced efficiency of transduction to the
retinal ganglion cell layer after intravitreal injection with mutant Y733F in AAV8
(2009). This discrepancy could be due to the capsid differences between AAV8
and AAV8BP2, which was designed more specifically for transduction of retinal
bipolar cells. Although closer to the visual field than photoreceptors, retinal
ganglion cells are even closer than bipolar cells and therefore are more easily
accessible. It should also be noted that the mice used in the experiment where
older than those used in subsequent experiments and displayed severely thinned
ONLs, and likely should be repeated to concretely support or refute our findings.
While intravitreal delivery of rAAV does have some advantages over subretinal
delivery, including ease of access and ability to target cells of the inner nuclear
layer (INL) with greater efficiency, a study by Qiuhong et al, demonstrated that
intravitreal administration of AAV vectors generated a humoral immune response
against the capsid that blocked vector expression upon intravitreal administration
in the contralateral eye (2008).

We

demonstrate

that

AAV8BP2(Y733F),

AAV8BP2(Y447F),

and

AAV8BP2(Y447F,Y733F) outperform parental serotype AAV8BP2 in vitro when
transducing HEK293 cells, but that only AAV8BP2(Y733F) outperforms AAV8BP2
in vivo. Interestingly, AAV8BP2(Y447F) appears to be less potent than AAV8BP2
in vivo. Upon mutating tyrosine to phenylalanine, it is predicted that capsid
structure would be preserved due to the hydrophobicity of both amino acid
residues. However, the hydroxyl group on the aromatic ring of tyrosine makes this
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residue less hydrophobic than phenylalanine. One possibility for the perceived
lower transduction efficiency of Y447F could be structural differences between the
two vectors that caused either insufficient binding to retinal cellular receptors or
endosomal escape. This finding correlates with results using tyrosine-mutated
AAV8 in which the Y733F mutant achieved much higher transgene expression
overall than the Y447F mutant (Petrs-Silva, et al., 2009). This finding was
expanded upon by Kotterman et al, when they discovered that serum NAbs titers
in NHPs correlated with those in the vitreal fluid, demonstrating that the intravitreal
route of administration exposes AAV capsid epitopes to the adaptive immune
system and that serum NAb measurements are predictive are of NAb titers in the
vitreous (2015). These studies suggest that, much like has been observed in other
organ systems, pre-existing antibodies to AAV should be considered when using
intravitreal gene delivery in contrast to the use of subretinal gene delivery.

We documented higher expression of the eGFP transgene in RPE cells and
photoreceptors with AAV8BP2(Y733F) as compared to the parental serotype. One
surprising result from this study was the lack of retinal bipolar cell transduction with
all vectors upon subretinal administration. We don’t believe that this outcome was
the effect of tyrosine mutagenesis because the same observation was made with
AAV8BP2, which was designed specifically to target bipolar cells (Cronin et al.,
2014). It is likely that the vector dosages used in order to discern a larger range in
potency differences were not high enough for the vector distribution to include the
inner nuclear layer. Subsequent studies evaluating the cellular tropism of these
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vectors should use a higher dose to observe if this prediction is true. Regardless,
the optimized capsid-mutant AAV vectors expand the current toolbox for basic
research question and therapeutic applications of gene-transfer to photoreceptors.
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Methods
Mutagenesis of AAV8BP2 capsid
Site-directed mutagenesis of surface-exposed tyrosine residues 447 and 733 to
phenylalanine on the AAV8BP2 capsid was performed using In-Fusion primers
(Clontech; Mountain View, CA, USA) to introduce the necessary adenosine to
thymidine mutation in these codons. Upon sequencing of these mutations, the
double tyrosine-mutant vector AAV8BP2(Y447F,Y733F) was created using
restriction enzymes HF-SanDI (KflI) and HF-Eco32I (Thermo Scientific; Waltham,
MA, USA) to digest both single tyrosine-mutant plasmids prior to gel purification of
the fragments of containing each mutation and ligation. The presence of the
expected mutations was again confirmed by sequencing.

Generation of viral GFP reporter vectors
The AAV proviral vectors consisted of the CMV enhancer and CBA promoter, the
cDNA encoding eGFP, and the bovine growth hormone (bGH) polyadenylation
signal. The rAAV was manufactured by the Research Vector Core at the Center
for Advanced Retinal and Ocular Therapeutics (CAROT) at the University of
Pennsylvania Perelman School of Medicine. The virus was manufactured after
triple transfection of HEK293 cells and was isolated and purified by
microfluidization, filtration, cation exchange chromatography (POROS 50HS; HE
Healthcare, Piscataway, NJ), density gradient ultracentrifugation and diafiltration
in phosphate-buffered saline (PBS). This combination provides highly purified,
transgene cassette-containing AAV particles and efficiently removes empty
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capsids and residual cesium chloride. The purified virus, along with 0.001%
Pluronic F-68 (PF68BASF, Ludwigshafen, Germany), was then passed through a
0.22-μm filter and stored frozen (–80°C) in sterile tubes until use. Quality control
procedures included sodium dodecyl sulfate-polyacrylamide gel electrophoresis
and silver staining (for vector purity), real-time quantitative polymerase chain
reaction (to assess vector genome concentration), osmolality, pH, and endotoxin
testing.

In vitro transduction
Approximately 3E5 HEK293 cells were plated in each well of a 6-well plate in 2
mLs of Dulbecco’s modified Eagle’s medium (DMEM) (Gibco; Gaithersburg, MD,
USA) supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich; St. Louis,
MO, USA) and 1% penicillin/streptomycin (Gibco; Gaithersburg, MD, USA) and
cultured at 37°C and 5% CO2 so that the next day they were 50% confluent prior
to transduction. Each well was transduced with one of the five vectors in Opti-MEM
reduced serum media (Gibco; Gaithersburg, MD, USA) using a multiplicity of
infection (MOI) of 10,000. The cells were incubated in the virus-containing media
for 24 hours before cells were collected for subsequent analysis.

RT-qPCR and western blot analysis
RNA was extracted from HEK293 cells and single dissected murine retinas (as
previously described) using the PureLink RNA Mini Kit (Invitrogen; Carlsbad, CA,
USA) and quantified using a NanoDrop (Thermo Scientific; Mountain View, CA,
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USA) prior to conversion of 1.5 μg of total RNA to single-stranded cDNA using the
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems; Foster City,
CA, USA) (Siegert et al., 2012). The resulting cDNA was diluted 1:10 in RNasefree water and a 5 μL volume was used per well to perform qPCR with Platinum
SYBR Green qPCR SuperMix-UDG (Invitrogen; Carlsbad, CA, USA) with forward
and reverse primers for eGFP. Samples were loaded in triplicate. GAPDH was
used as the endogenous reference sequence to normalize expression levels in
these experiments. Previously confirmed GFP-positive total RNA was used as an
exogenous positive control to determine whether the samples contained any
components that inhibited reverse transcription or qPCR. Wells containing the
SYBR Green master mix and either eGFP or GAPDH primers without cDNA were
used as negative controls. Relative quantification was performed as previously
described (Pfaffi, 2001).

Protein extraction was performed on two pooled dissected murine retinas for each
of the five AAV vectors and one dissected retina for the PBS injected and
uninjected retinas using RIPA Lysis and Extraction Buffer (Thermo Scientific;
Mountain View, CA, USA) supplemented with cOmplete, Mini, EDTA-free Protease
Inhibitor Cocktail tablets (Roche; Basel, Switzerland). Retinas were manually
homogenized prior to sonification and centrifugation at 13,000 xg for 15 minutes
at 4°C. Protein quantification was performed using Pierce BCA Protein Assay Kit
(Thermo Scientific; Mountain View, CA, USA) and 10 μg of each total protein
extract was loaded into one well of a 10 well, 1.5 mm 4-12% Bis-Tris
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polyacrylamide gel (Life Technologies; Carlsbad, CA, USA) in MES buffer (SigmaAldrich; St. Louis, MO, USA) to resolve the 32.7 kDa eGFP protein. Western
blotting transfer to a nitrocellulose membrane was performed using the iBlot 2 Gel
Transfer Device (Thermo Scientific; Carlsbad, CA, USA) with the preprogrammed
P0 7-minute method. Protein transfer was visualized by Ponceau Red (SigmaAldrich; St. Louis, MO, USA) staining of the membrane to ensure equivalent protein
loading concentration in each lane before washing in 1% TBST and blocking in 5%
milk (catalog number) in 1% TBST. The membrane was incubated at 4°C overnight
with rabbit anti-GFP primary antibody (manufacturer; catalog number) and for one
hour at room temperature with anti-rabbit HRP-conjugated secondary antibody
(manufacturer; catalog number). Pierce ECL Plus Western Blotting Substrate
(Thermo Scientific; Carlsbad, CA, USA) was used to detect HRP substrate for
laser-based imaging. The membrane was washed in Restore Western Blot
Stripping Buffer (Thermo Scientific; Carlsbad, CA, USA) and incubated with rabbit
anti-GAPDH primary antibody (manufacturer; catalog number) as a loading control
in the same manner as described above before imaging the membrane a second
time.

In vivo transduction by intravitreal and subretinal routes of administration
In the first in vivo experiment, female CD1 mice aged 18 months were administered
1E10 vg of one of three different sub-serotypes of AAV8BP2-eGFP under general
anesthesia. AAV reagent was thawed on ice and diluted to appropriate
concentration with PBS. Using a 5 μL syringe (65 RN, Hamilton Compant, Reno,
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NV, USA) one eye received a 1 μL subretinal injection and the other a 1 μL
intravitreal injection of the same sub-serotype. Two eyes were injected for each
combination of AAV8BP2 and delivery route. Between injections with different AAV
reagents, the needle and syringe were flushed at least 10 times with sterile PBS.
After the injections the ocular surface was dressed with PredG (prednisolone
acetate-gentamicin, 0.3%/0.6%; Allergan) ointment.

The second in vivo experiment used female C57Bl/6 mice aged >1 month. These
mice were subretinally administered 1 μL of 5E8 vg of one of four vectors (AAV8,
AAV8BP2, AAV8BP2(Y447F), or AAV8P(Y733F)) containing eGFP cDNA under
general anesthesia. Four eyes were injected for each vector. The injection and
post-injection procedures were performed as described above.

The third in vivo experiment used female C57B/6 mice aged >1 month. These mice
were subretinally administered 1 μL of 1E9 vg of one of five vectors (AAV8,
AAV8BP2, AAV8BP2(Y447F), AAV8P(Y733F) or AAV8BP2(Y447F,Y733F))
containing eGFP cDNA or sterile PBS as an injected control under general
anesthesia. Four eyes were injected for each vector with the exception of
AAV8BP2(Y447F,Y733F) in which six eyes were injected. Only two eyes were
injected with PBS control and two additional eyes were uninjected. The injection
and post-injection procedures were performed as described above.
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Fluorescent fundoscopy
Mice were anesthetized using 87.5 mg/kg of body mass of ketamine (Vetalar,
Zoetis, Florham Park, NJ, USA) and 10 mg/kg xylazine (Rompun, Bayer AG,
Leverkusen, Germany) administered via intraperitoneal injection using a 1 mL
syringe and 29 G needle. Ketamine and xylazine were mixed together with the
appropriate amount of sterile PBS. 1% (w/v) tropicamide and 2.5% (w/v)
phenylephrine (Bausch & Lombe, Bridgewater, NJ, USA) were applied to dilate the
pupils and enable visualization of the fundus. For each eye, a visible light and GFP
fluorescence image of the central view and each of the four peripheral views
(nasal, temporal, inferior, and superior) was taken. After the procedure mice were
allowed to wake up under a heat lamp before being returned to their enclosures.

Retinal tissue processing and immunohistochemistry
Eyes were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS)
before overnight cryopreservation at 4°C with 30% sucrose. Eyes were then
embedded in Optimal Cutting Temperature (OCT) compound (manufacturer; city)
and frozen in a slurry of dry ice and isopentane (Sigma-Aldrich; St. Louis, MO,
USA) before cryosectioning. Immunohistochemistry was carried by incubating
sections at 4°C overnight in staining solution containing rabbit anti-CAR primary
antibody (manufacturer; city) and for two hours at room temperature with goat antirabbit IgG Alexa Fluor 555 (Invitrogen; Carlsbad, CA, USA) secondary antibody
for fluorescent visualization. Fluoromount-G with DAPI (Invitrogen; Carlsbad, CA,
USA) was used to mount and counterstain the sections for nuclear localization.
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Figure 3.1. Mutagenesis of tyrosine residues on the AAV8BP2 capsid to phenylalanine
(A) The AAV8BP2 capsid plasmid is derived from the AAV8 parental serotype and contains a
small stretch of mutated DNA. (B) Tyrosine is a polar, uncharged amino acid that possesses a
hydroxyl group in an aromatic ring, making it a derivative of phenol. This hydroxyl group is
subjected to phosphorylation posttranslation modification. E3 ubiquitin ligase specifically
stimulates the ubiquitination of phosphotyrosine-containing proteins. Mutating these tyrosine
residues to phenylalanine, a nonpolar amino acid, facilitates viral nuclear transport by limiting
proteasome-mediated degradation. The hydrophobic aromatic side chain of both tyrosine and
phenylalanine should preserve the AAV capsid structure.
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Figure 3.2. In vitro transduction of HEK293 cells with tyrosine-mutant AAV8BP2 and
parental capsids
HEK293 cells were incubated for 24 hours in AAV-containing media prior to collection and RNA
extraction. RT-qPCR to determine the relative quantity of eGFP transcription was performed for
all samples and normalized to housekeeping gene GAPDH. AAV8BP2(Y733F), and AAV8
showed a statistically significant increase in eGFP mRNA with ***P<0.001 for Y733F and AAV8
versus AAV8BP2 Statistical analysis was performed with one-way ANOVA plus Dunnett’s
multiple range test compared to the control group (AAV8BP2).
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intravitreal delivery

subretinal delivery

Figure 3.3. Fluorescent fundoscopy of in vivo transduction in older CD1 mice with
subretinal and intravitreal administration of 1E10 vg AAV vectors
Fundus imaging was performed on all mice four weeks post-injection. Above are
representative images of the transduction profile of each of the AAV8BP2 vectors when
delivered either subretinally or intravitreally.
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Figure 3.4. Fluorescent fundoscopy of in vivo transduction in C57Bl/6 mice with
subretinal administration of 5E8 vg of AAV vectors
(A) Representative retinal fundus views using white light and FITC illumination to identify
pigmentary changes and eGFP-positive cells, respectively. (B) Relative quantification of eGFP
transcription in single dissociated retinas was normalized to housekeeping gene GAPDH.
AAV8BP2(Y733F) showed a statistically significant increase in eGFP mRNA with **P<0.01 for
Y733F versus AAV8BP2. Statistical analysis was performed with one-way ANOVA plus
Dunnett’s multiple range test compared to the control group (AAV8BP2).
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Figure 3.5. Fluorescent fundoscopy of in vivo transduction in C57Bl/6 mice with
subretinal administration of 1E89 vg of AAV vectors
(A) Representative retinal fundus views using white light and FITC illumination to identify
pigmentary changes and eGFP-positive cells, respectively. (B) Relative quantification of
eGFP transcription in single dissociated retinas was normalized to housekeeping gene
GAPDH. (C) Western blot analysis of eGFP protein from two dissociated retinas injected with
the same rAAV vector.
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Figure 3.6. Evaluation of in vivo cellular tropism of tyrosine-mutant AAV8BP2 capsids
in the C57Bl/6 mouse retina upon subretinal administration through localization of the
GFP transgene
(A) Fluorescent immunohistochemistry visualization of retinal cryosections stained with cone
photoreceptor marker CAR and DAPI nuclear stain with a low dose (5E8 vg) of AAV vector.
All AAV8BP2 vectors target RPE cells, but only AAV8BP2 and Y773F additionally target
photoreceptors (B) Immunohistochemistry analysis of cellular tropism of AAV8BP2 vectors
upon high dose (1E9 vg) administration.
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Abstract
Mutations in the Crumbs homologue 1 (CRB1) gene account for 10-15% of all LCA
cases. Understanding the disease pathology is pivotal for therapeutic
development. However, in vivo functional studies of CRB1 are complicated by the
differential expression pattern of CRB1 between human and murine retinas. Here,
we present our differentiation of CRB1-associated LCA (LCA8) patient-derived
induced pluripotent stem cells (iPSCs) to retinal progenitor cells (RPCs) as a model
to investigate the early stages of pathophysiology. Immunohistochemistry and
qRT-PCR were used to assess expression of RPC markers and developmental
signaling pathways, Wnt and Notch. Flow cytometry was used to quantify EdU
labeling of proliferating RPCs. Early RPCs lost expression of pluripotency markers
and began expressing eye field transcription factors by day 7 of the differentiations.
EdU staining revealed differences in the number of proliferating cells between
CRB1-/- and control RPCs between day 14 and 21. We observed altered
expression of several Wnt signaling pathway components. The increased
proliferative rates of CRB1-/- RPCs correlates with the murine models and human
clinical phenotypes of hyperproliferation of the neural retina, establishing a model
for studying the cellular and molecular phenotypes of CRB1-associated LCA.

103

Introduction
Leber’s congenital amaurosis (LCA) is a group of the most severe inherited
retinopathies affecting 1 in 81,000 individuals (Stone, 2007). LCA is characterized
by blindness from birth or progressive retinal and visual dysfunction within the first
year of life (Fulton et al., 1996; Cremers et al., 2002). Symptoms include reduced
or nonrecordable electroretinogram and pupillary light reflexes, nystagmus, and
oculodigital reflexes (den Hollander et al., 2008). Mutations in any of 18 genes that
encode proteins with varying retinal functions cause LCA (McKusick and Kelly,
2015). LCA8 accounts for 10-15% of all LCA cases and is attributed to mutations
in the crumbs homologue 1 (CRB1) gene (den Hollander et al., 2001; Lotery et al.,
2001). In a healthy retina, CRB1 functions as a structural and signaling
transmembrane protein. The cytoplasmic domain docks an evolutionarily
conserved protein scaffold known as the Crumbs (Crb) complex at the subapical
region above adherens junctions in mammalian photoreceptors and Müller glia (Fig
4.1A) (Roh et al., 2002; Li et al., 2014; Pellissier et al., 2014). CRB1 exerts its
function in maintaining cell-cell adhesion, intracellular communication, and apicalbasal polarity through the Crumbs complex and other transient effectors
(Thompson et al., 2013).

There is currently no treatment for patients afflicted with CRB1-LCA, but recent
success with ocular genetic therapy for RPE65-LCA offers a novel treatment
strategy for loss-of-function retinal diseases (Simonelli et al., 2010). RPE65 gene
therapy utilizes recombinant replication-defective AAVs to stably transduce RPE
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cells with a corrected version of RPE65. Gene replacement of mutant CRB1 would
exploit this same strategy, except target photoreceptors and/or Müller glia. High
levels of stable expression with no apparent toxicity is expected upon therapeutic
intervention as long as photoreceptor degeneration is delayed (Acland et al.,
2005). Gene therapy ameliorates structural or functional deficits, but it may be
difficult or impossible to intervene in the appropriate timeframe with developmental
disorders. While photoreceptor degeneration is common to all forms of LCA, the
genetic and clinical heterogeneity and early age of onset makes ascertaining
pathogenesis difficult (Fig 4.1B). It is currently unknown whether CRB1 mutations
cause purely degeneration or aplasia with end-stage retinal deterioration. Defining
the disease mechanism for CRB1 mutations is pivotal for employing potent
therapeutic strategies.

Generation of specific post-mitotic retinal cells occurs in a temporally successive
manner from a pool of polarized progenitor cells (Livesey and Cepko, 2001).
Initiation of differentiation is dependent upon the termination of progenitor
proliferation. Cell adhesion and polarity complexes, such as the Crumbs complex,
are thought to be critical regulators of this transition because of their role in
asymmetric division, which generates daughter cells that can adopt differing fates
during development (Martin-Belmonte and Perez-Moreno, 2011). Intrinsic
asymmetric architecture ensures the inheritance of different cell fate determinants
upon division and is one mechanism by which cell specification occurs. Loss of
cell polarity, and consequently asymmetric division, is linked to excessive self105

renewal (Betschinger et al., 2006). Examination of LCA8 patient retinas with in vivo
OCT reveals remarkable thickness and abnormal laminar organization, consistent
with progenitor overproliferation (Fig 4.1B) (Jacobson et al., 2003). This
hyperplastic phenotype contrasts with the thinning due to the degeneration of the
cellular structure observed in the retinas of patients with mutations in other LCAassociated genes and suggests that developmental defects underlie CRB1-LCA
rather than the more typical degenerative mechanism of LCA pathogenesis (Milam
et al., 1998; Jacobson et al., 1998; Jacobson et al., 2000).

In vivo functional studies of CRB1 are complicated by the differential cellular
expression patterns of CRB1 between human and murine retinas. In humans,
CRB1 expression is restricted to photoreceptors and Müller glia. In mice, Crb1 is
solely expressed in Müller glia while the mammalian paralog Crb2 is expressed in
photoreceptors, Müller glia, and other epithelia (Pellissier et al., 2014). Although
the Crb1Crb2 cKO mouse model exhibits several clinical characteristics observed
in LCA patients, whether CRB1 and CRB2, which differ in their extracellular
domains, serve redundant or unique functions has yet to be determined (Pellissier
et al., 2013).

To overcome this challenge, we utilized CRB1-LCA patient-derived induced
pluripotent stem cells (iPSCs) differentiated into retinal progenitor cells (RPCs) as
a model to study the role of human CRB1 in retinal development. iPSC technology
provides a unique opportunity to generate personalized models of disease to be
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used in a variety of studies that can be extrapolated to humans, from determining
pathology to demonstrating intervention efficacy (Cereso et al., 2014). The results
of my experiments help to elucidate the role of CRB1 during the critical switch from
retinal progenitor

cell proliferation

to

differentiation.

Understanding

the

pathophysiology of CRB1 mutations during retinal development is essential for
informing potential treatment strategies and defining treatment recipient
populations. For example, alternative pathogenic variants of CRB1 instead cause
the more common and milder retinal dystrophy, retinitis pigmentosa (RP) (den
Hollander et al., 1999). In comparison to LCA patients, a later age of onset and
slower disease progression in RP patients offers greater flexibility for gene therapy
interventions. Although gene transfer may not be an appropriate treatment for
CRB1-LCA patients, it may still be beneficial for CRB1-RP patients.
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Results
Generation of LCA8 patient-specific iPSCs from PBMCs
We collected PBMCs from two unrelated CRB1-associated LCA patients (CRB1-/) and three healthy-sighted controls (CTRL) to generate iPSC lines (Fig 4.2A).
Multiple clones of each line were expanded to account for changes that may occur
as the clones reach higher passage numbers. These iPSCs were screened for
pluripotency characteristics to confirm the health of the lines before proceeding
with differentiations. These features include including morphology, surface marker
expression, gene expression, Sendai virus expression, and karyotype (Fig 4.3A,CF). Additionally, the CRB1 mutations in each of these lines was confirmed through
sequencing. One patient harbored a homozygous cysteine to tyrosine mutation at
amino acid 948 (C948T) while the second patient had compound heterozygous
mutations (Fig 4.3B). One allele had the same C948T mutation as observed in the
first patient, but the second allele had a mutation in leucine residue 751 encoding
for an early stop codon (L751Stop).

RPC generation from CRB1-/- and CTRL iPSC lines
To differentiate these CRB1-/- and CTRL iPSC lines to RPCs, we aimed to
recapitulate the in vivo development environment in our two-dimensional (2D)
cultures as closely as possible. Organogenesis of the vertebrate eye begins with
a pair of evaginations of the neuroepithelium from the neural tube mediated by the
retinal homeobox transcription factor, RAX (Furukawa et al., 1997; Mathers et al.,
1997; Voronina et al., 2004; Rembold et al., 2006). These diverticula extend from
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the diencephalon and form hollow bulbs known as the optic vesicles. At this stage,
the progenitors of the neuroepithelium have the potential to differentiate into the
inner neural retina or the outer RPE. These cells are characterized by the
expression of RAX as well as other key regulators of eye field specification, PAX6,
LHX2, SIX3, and SIX6 (Zuber et al., 2003). Ubiquitous expression of the
microphthalmia transcription factor (MITF) regulated by OTX2 in the optic vesicle
controls the bipotentiality of the neuroepithelium (Nguyen and Arnheiter, 2000;
MartÍnez-Moral et al., 2003). The subsequent downregulation of these two
transcription factors by VSX2 in the distal region and extrinsic signaling of
fibroblast growth factors (FGF) from the overlying ectoderm initiate domain
specification and define the population of inner retinal progenitor cells (RPCs)
(Rowan et al., 2004; Horsford et al., 2005; Pittack et al., 1997; Hyer et al., 1998).
Presumptive RPE will continue to express MITF.

Interactions with the surface ectoderm and extraocular mesenchyme initiate a
thickening of the ectoderm into the lens placodes, which cause an axial
invagination of the distal portion of the optic vesicles to form the optic cups. These
structures consist of an RPE and neural retinal progenitor bilayer of cells. RPCs
then proliferate to form a stratified structure, eventually giving rise to lineagerestricted precursor cells that will mature into postmitotic retinal neurons and Müller
glia. Through the addition and removal of exogenous factors in the media at
specific timepoints during the course of the differentiation, we were able to guide
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the iPSC into cell populations reminiscent of early stage retinal development (Fig
4.2B). These junctures were confirmed by probing for expression of the specific
cell surface markers that denote each developmental phase.

Early RPCs lost expression of pluripotency markers OCT4, NANOG, and DNMT3B
and began expressing eye field transcription factors SOX1/2, RAX, PAX6, SIX3,
and LHX2 by day 7 of the differentiations (Fig 4.4A-C). Importantly, expression of
RAX was downregulated by day 7 of the differentiations, consistent with
progressive retinal development (Fig 4.4B,C). CRB1 and CRB2 expression was
observed as early as day 7 and expression continued to increase throughout
retinal patterning (Fig 4.4D). This is informative because we can begin to narrow
down the timepoint in which we might potentially see a noticeable phenotype
between the CRB1-/- and CTRL cell lines. It should be noted that the C948T CRB1
mutation results in a splicing defect that effects the mRNA, so CRB1 is transcribed,
but not translated into a functional protein, which is why we observe expression in
our CRB1-/- cell lines and differences in expression between the homozygous and
compound heterozygous lines. As the differentiations progress through day 21, we
see expression of photoreceptor precursor marker CRX and retinal ganglion cell
marker BRN3A, suggesting that at this timepoint we have surpassed the retinal
progenitor switch to terminal differentiation we are interested in examining to
determine if there is a hyperplastic phenotype between our CRB1-/- and CTRL lines
(Fig 4.4E).
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Determining a phenotype in CRB1-/- RPC cultures
To determine the relative timepoint in which our cultures were at the critical
transition of retinal progenitor cell proliferation to terminal differentiation, we
performed an MTT assay at several timepoints throughout the differentiation. The
MTT assay is a colorimetric assay used to measure cell metabolic activity. In
essence, greater metabolic activity reduces the MTT substrate to an insoluble form
that is purple in color, translating into a more intense colorimetric payoff. Therefore,
it is a secondary reflection under certain conditions of the number of viable cells
present. By plating an equal number of cells from each line at different timepoints,
the assay can be used as a preliminary experiment to determine possible
differences in proliferation. We observed an increase in proliferation of CRB1-/cultures compared to CTRL cultures at day 14 post-induction of differentiation (Fig
4.5A). As the cultures matured through day 18, the proliferative capacity of all lines
decreased suggesting that RPCs were differentiating between these two
timepoints.

Examination of the CRB1-/- and CTRL RPC cultures at day 14 post-induction of
differentiation revealed a significant increase cyclin D2 (CCND2) expression in
CRB1-/- cultures (Fig 4.5B). Synthesis of cyclin D2 is initiated during the G1 phase
of mitosis and is the main cyclin D driving the G1/S transition in neuroprogenitors
(Glickstein et al., 2006). It functions as a regulator of cyclin-dependent kinases
CDK4 and CDK6 (Bouchard et al., 1999). The cyclin D2-Cdk4/6 complex initiates
a signaling cascade that induces expression of cyclin E, which is important for S
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phase progression (Siu et al., 2012). Cyclin E expression is not significantly
different between the CRB1-/- and CTRL RPC cultures, suggesting that there are
more CRB1-/- progenitors in the G1 phase of mitosis. To determine the percentage
of cells at day 14 actively undergoing mitosis between the cultures, we performed
flow cytometry with EdU (S-phase marker) and Ki67 (general cell cycle marker).
We observed a greater percentage of EdU+/Ki67+ cells in the CRB1-/- cultures as
compared to the CTRL cultures (Fig 4.5C,D).

To further characterize the observed higher percentage of proliferating cells in
CRB1-/- cultures at day 14, we analyzed the expression of several different
components of the Notch and Wnt by RT-qPCR, both of which have been
suggested to be influenced by CRB1 (Alves et al., 2014). No significant differences
were detected in expression of Notch signaling pathways components between
the CRB1-/- and CTRL cultures (Fig 4.6A). However, we observed altered
expression of several Wnt signaling pathway components including significant
differences in expression of AXIN2, LEF1, TCF7, and WNT3a (Fig 4.6B).
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Discussion
New IRD model systems are useful in studying both pathogenesis and the effects
of AAV-mediated gene augmentation. Despite the large number of spontaneous
and genetically engineered IRD mice, it is impossible to have an animal model for
each causative gene that replicates the phenotypes observed in humans, let alone
all the possible mutations of a gene, a consideration that is particularly important
for the development of gene therapies. iPSC technology offers a unique
opportunity to generate humanized developmental and disease models by
reprogramming a patient’s skin or blood cells and differentiating them into the
retinal cells of interest using one of many differentiation strategies.

We used this strategy with LCA8-patient specific iPSC to determine if early
developmental pathology underlies end-stage retinal degeneration. This approach
is especially suited for this type of analysis given that iPSC differentiations
represent the earliest stages of cell-specific and tissue development. Additionally,
over 150 mutations in the exome and protein coding domains of CRB1 have been
identified to cause either LCA, early-onset RP, or RP (den Hollander et al., 2004).
Currently, there is no clear genotype-phenotype correlation – patients harboring
the same mutations can present with differing degrees of symptom severity
(Bujakowsa et al., 2012). This insinuates that additional modifying factors, either
genetic or environmental, are responsible for the modulation of the phenotype in
patients harboring CRB1 mutations, making the use of patient-specific iPSC as
personalized disease models even more attractive.
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We achieved highly enriched adherent RPC cultures from patient-derived iPSC
lines characterized by the temporally appropriate expression of eye field
transcription factors necessary for development of retinal cell lineages. In vitro
neural retinal differentiations require several sequential steps beginning with the
induction of an anterior neural fate by inhibition of Wingless (Wnt) and bone
morphogenic protein (BMP) (Moon et al., 1997; Piccolo et al., 1996; Glinka et al.,
1997; Lee et al., 2004; Liu et al., 2010). In these experiments, we used small
molecules XAV939 and LDN193189 to inhibit Wnt and BMP, respectively.
Supplementary inhibition of TGFβ with small molecule SB43152 in combination
with nicotinamide (NIC), an amide of vitamin B3 that promotes neuralization, and
insulin-like growth factor 1 (IGF1) encourages eye field specification. Sequential
addition of basic fibroblast growth factor (bFGF) eventually confers retinal
progenitor identity.

The unusually thick appearance of LCA8 retinas is in stark contrast to the thinning
retinas observed in patients with LCA mediated by other causative genes. Alves
et al showed that loss of CRB1 and CRB2 in murine retinas leads to cell cycle
defects and increased proliferation (2013). Keeping in mind the function of CRB
proteins in maintaining cell polarity through the Crumbs complex, these findings
led us to hypothesize that loss of CRB1 in the human retina results in
overproliferation of retinal progenitor cells due to the mislocalization or altered
expression of apical polarity complex components (Fig 4.7). These complexes
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influence cell specification by playing a role in the asymmetric division of RPC
daughter cells (Martin-Belmonte and Perez-Moreno, 2011). We identified
differences in the number of proliferating cells between CRB1-/- and CTRL RPCs.
In addition, we found that altered expression of Wnt signaling pathway components
may partially explain this phenomenon.

Wnt signaling is a key regulator of retinal development, including establishing the
retinal field and maintaining RPC identity (Lad et al., 2009). Although direction
interaction of CRB proteins and Wnt pathway components has yet to be
demonstrated, it has been suggested that the Crumbs complex as an integral part
of the adherens junction formation may act as a regulator of Wnt because Wnt
proteins β- and P120-catenin require the adherens junction for correct localization
(Bulgakova and Knust, 2009). Work by Pellissier et al. demonstrated
mislocalization of both proteins and increased P120-catenin in murine retinas
lacking CRB1 and CRB2 (2013). Therefore, in CRB1-/- RPCs, increased P120catenin levels could prevent downstream binding partner Kaiso from translocating
to the nucleus to inhibit Wnt target genes, such as cMyc, cyclin D1, and Wnt11.

Our data suggests trending upregulation of Wnt signaling pathway players. LEF1
and TCF7 expression in CRB1-/- RPCs was significantly different from expression
in CTRL RPCs. These genes encode for transcription factors that interact with
nuclear β-catenin to induce transcription of a genetic network important for cell
cycle regulation and cell fate decisions, corroborated our findings regarding the
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increased percentage of actively proliferating CRB1-/- RPCs (Moon et al., 2002).
The increased proliferative rates of CRB1-/- RPCs correlates with the murine model
data and human clinical phenotypes of hyperproliferation of the neural retina,
establishing a model for studying the cellular and molecular phenotypes of CRB1associated LCA.
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Methods
Generation and maintenance of iPSCs cultures from PBMCs
iPSC reprogramming from PBMCs taken from two unrelated CRB1-associated
LCA patients and three healthy-sighted controls was performed using sendai virus
mediated gene transfer as previously described (Yang et al., 2012). Cell lines were
passaged 15 times prior to expansion and freezing down of stocks in Freezing
Media (ATCC; Manassas, VA, USA) for use in retinal differentiations to ensure
complete reprogramming. Pluripotency assays were performed and expected
genetic mutations were assessed through sequencing. Cell lines were karyotyped
to confirm the absence of chromosomal abnormalities.

iPSCs were maintained on irradiated mouse embryonic fibroblasts (MEFs) made
in-house and plated on wells coated with 0.1% gelatin at an optimal density prior
to overnight incubation. DMEM/F12 (Gibco; Gaithersburg, MD, USA) base media
was

supplemented

with

20%

Knock-out

Serum

Replacement

(Gibco;

Gaithersburg, MD, USA), 2 mM L-glutamine (Gibco; Gaithersburg, MD, USA),
.0001M non-essential amino acids (Invitrogen; Carlsbad, CA, USA), 1%
penicillin/streptomycin (Gibco; Gaithersburg, MD, USA) 55 μM 2-mercaptoethanol
(Gibco; Gaithersburg, MD, USA), and 5 ng/mL of bFGF to make hESC
maintenance media. Media was changed daily and fresh media was made weekly.
Cells were cultured in hypoxic humidified incubators at 37°C and 5% CO2 and
passaged using TrypLE (Gibco; Gaithersburg, MD, USA) and mechanical
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dissociation. All cell lines were routinely examined for pluripotency markers using
immunofluorescence staining and flow cytometry analysis for SSEA3 and SSEA4.

iPSC 2D differentiation to RPC
TrypLE was used to clear cultures of all MEF contamination before addition of
Accutase (Sigma-Aldrich; St. Louis, MO, USA) and incubation at 37°C to produce
a single-cell suspension. Before the start of each experiment, iPSCs were seeded
to confluency on plates coated with Matrigel (BD Science, San Jose, CA, USA) for
feeder-free culturing. Cells were maintained in 50% hESC and 50% MEFconditioned media supplemented with 20 ng/mL of bFGF. The following day
cultures were again treated with TrypLE and Accutase before seeding to
confluency on Matrigel-coated plates. Cultures were allowed to grow to complete
confluency for 1-2 days in normoxic conditions before induction of differentiation.

Differentiation media consisted of DMEM/F12 with 2% B27 and 1% N2 (Invitrogen,
Carlsbad, CA). From differentiation day 0 to day 4, media was supplemented with
100 nM LDN193189 (Stemcell Technologies; Vancouver, Canada), 10 nM
SB43152 (Stemcell Technologies; Vancouver, Canada), 2 μM XAV939 (Tocris,
Bristol, United Kingdom), and 10 mM NIC. On differentiation day 5 NIC was pulled
and 20 ng/mL bFGF was added to the media and this formula was maintained
throughout the remainder of the experiments.
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RT-qPCR
Cultures were collected at days 7, 14, and 21 post-induction of differentiation. RNA
was extracted using the PureLink RNA Mini Kit (Invitrogen; Carlsbad, CA, USA)
and quantified using a NanoDrop prior to conversion of 1.5 μg of total RNA to
single-stranded cDNA using the High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems; Foster City, CA, USA). The resulting cDNA was diluted 1:10
in RNase-free water and a 5 μL volume was used per well to perform qPCR with
TaqMan Fast Advanced Master Mix (Applied Biosystems; Foster City, CA, USA)
with TaqMan probes with FAM quencher for eye field, RPC, and immature retinal
cell precursor markers or cell cycle, Wnt, and Notch signaling pathway
components. Samples were loaded in triplicate. TUBB3 TaqMan probe with VIC
quencher was used as the endogenous reference sequence in the same wells as
the experimental probes to normalize expression levels in these experiments.
Wells containing the TaqMan master mix and primer probes without cDNA were
used as negative controls. Relative quantification was determined performed as
previously described using cDNA collected from iPSC to determine expression
changes from baseline (Pfaffi, 2001).

Immunofluorescence
One day prior to days 7, 14, and 21 post-induction of differentiation, cultures were
dissociated to single-cell suspensions in Accutase (Sigma-Aldrich; St. Louis, MO,
USA) with the addition of DNase (Invitrogen; Carlsbad, CA, USA). Cells were
centrifuged at 300xg for five minutes at 20°C before aspiration of Accutase solution
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and resuspension in 10 mL of PBS. 20 μL of this suspension was combined with
20 μL of Trypan Blue (Gibco; Gaithersburg, MD, USA) and 10 μL was placed under
a hemocytometer coverslip to determine the cell count. 100,000 cells were seeded
per well in an 8-well Matrigel-coated chamber slide and allowed to incubate at 37°C
overnight. Cells were then fixed using 4% paraformaldehyde (R&D Systems;
Minneapolis, MN, USA) in PBS for 15 minutes at 4°C and then washed with PBS
for 10 minutes three times. For staining, cells were permeabilized and blocked for
one hour at room temperature in 10% goat serum, 0.3% BSA, and 0.2% Triton X100 (Gibco; Gaithersburg, MD, USA) in PBS. Cells were briefly washed with PBS
staining with primary antibody at manufacturer suggested dilution in 10% goat
serum, 0.3% BSA, and 0.l1% Triton X-100 in PBS. Chamber slides were in
humidified container at 4°C in the dark overnight. Cells were washed with PBS
three times before appropriate secondary antibody staining at a dilution of 1:1000
in same reagent as primary antibody staining for two hours in a dark container at
room temperature. Cells were washed with PBS three times and allowed to dry
before chamber well divider was removed from slide. Fluoromount-G with DAPI
(Invitrogen; Carlsbad, CA, USA) was to mount coverslips. Slides were viewed with
a Zeiss light microscope.
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MTT Assay
One day prior to days 7, 14, and 21 post-induction of differentiation, cultures were
dissociated to single-cell suspensions in Accutase with the addition of DNase.
Cells were centrifuged at 300xg for five minutes at 20°C before aspiration of
Accutase solution and resuspension in 10 mL of PBS. 20 μL of this suspension
was combined with 20 μL of Trypan Blue and 10 μL was placed under a
hemocytometer coverslip to determine the cell count. 10,000 cells were seeded
per well in a Matrigel-coated 96-well plate and allowed to incubate at 37°C
overnight. Media was aspirated from wells and 50 μL of differentiation media and
50 μL of MTT solution was added to each well. Plates were incubated at 37°C for
three hours. After incubation, 150 μL of MTT solvent was added to each well. The
plate was wrapped in aluminum foil and placed on an orbital shaker for 15 minutes.
The absorbance was measured at 590 nm using Tecan plate reader and Magellan
software. Samples were plated in at least triplicate if not more and parallel wells
without cells were used as a sample background control to account for the serum
and phenol red in the differentiation media. Additionally, parallel wells without the
addition of MTT reagent were used as a solvent control. The average absorbance
reading for each sample was calculated and the culture medium background was
subtracted from the averaged sample reading.

EdU and anti-Ki67 labeling for flow cytometry
EdU labeling was performed with Click-iT EdU Flow Cytometry Assay Kit
(Invitrogen, Carlsbad, CA) containing Alexa Fluor 647 azide as described by the
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manufacturer with the exception of preparation of a 1X working solution instead of
2X. Cells were incubated with EdU for one hour. Cells were then harvested with
Accutase to get a single-cell suspension, centrifuged, and resuspended in 520 μL
of 1% BSA in PBS. This solution was split among five wells per sample into a Vbottom 96-well plate. The cells are pelleted and then allowed to incubate at room
temperature in the dark for 15 minutes in Click-It fixative. Cells were washed once
with 1% BSA in PBS, pelleted, and then allowed to incubate at room temperature
in the dark for 30 minutes in Click-It reaction cocktail. Cells were then washed with
Click-It permeabilization and wash reagent, pelleted, and resuspended in the same
reagent containing mouse anti-Ki67 (company; catalog number) at the dilution
suggested by the manufacturer and allowed incubation at room temperature in
dark for 30 minutes. Cells were then washed twice with permeabilization and wash
reagent and resuspended for a final time with PBS. The collection rate and number
of events were kept consistent for flow cytometry analysis for each sub-sample
(unlabeled negative control, EdU-labeled, Ki67-labeled, EdU and Ki67 doublelabeled, and an antibody isotype-labeled negative control).
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Figure 4.1. Mutations in CRB1 disrupt apical polarity complex formation in human
photoreceptors and Müller glia resulting in abnormally thick and disorganized retinas
(A) CRB1 localizes specifically to the subapical region (SAR; red) above adherens junction
(AJ; black) between rod and cone photoreceptors and Müller glia in human retinas. CRB1
functions as a structural and signaling transmembrane protein that docks an evolutionarily
conserved cytoplasmic scaffold integral for maintaining apical-basal polarity. (B) Spectral
domain optical coherence tomography (SD-OCT) retinal cross-sections through the fovea in
two patients with bi-allelic mutations in CRB1 compared to a normal subject illustrate a
spectrum of severity. P1 shows a maldeveloped, extremely thick and delaminated retina. The
nuclear layers (outer nuclear layer, ONL; inner nuclear layer, INL; ganglion cell layer, GCL)
are barely discernible. There is foveal thinning. The signal from the interdigitation (IZ band)
between the photoreceptor outer segments (POS) and the apical retinal pigment epithelium
are easily visible as a band in the normal subject, but is only detectable as fragmented
hyperreflectivities in P1. P2 shows a less severe phenotype with better laminated retina. The
nuclear layers are discernible. There is foveal thinning. Like in P1, the signal from the
interdigitation between POS and the apical RPE is only detectable as fragmented
hyperreflectivities (figure designed by Tomas Aleman, M.D.).
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Figure 4.2. Experimental approach used to study LCA8 pathophysiology
(A) Peripheral blood mononuclear cells (PBMCs) from patient blood samples are
reprogrammed with Sendai virus to induced pluripotent stem cells (iPSC). (B) These iPSC
undergo a 2D neural retina differentiation over the course of 21 days using soluble factors
meant to first neuralize and then direct cells towards an eye field fate. Addition of basic
fibroblast growth factor (bFGF) initiates RPC specification. In vivo, RPCs then proliferate to
form a stratified structure and eventually give rise to lineage-restricted precursor cells that will
mature into postmitotic retinal neurons and Müller glia.
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Figure 4.3. Characterization of LCA8 iPSC lines
Both iPSC lines were screened for pluripotency characteristics including (A) morphology, (C)
surface marker expression, (D) gene expression, (E) Sendai expression, and (F) karyotype.
(B) One patient harbors a homozygous Cys948Tyr mutation while the second patient has
compound heterozygous Cys948Tyr and Leu751Stop mutations in CRB1.
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Figure 4.4. RPC populations differentiate from patient-derived iPSC and express
temporally appropriate eye field markers
(A) RPC cultures down-regulate expression of pluripotency genes by day 7 (B) and begin to
express key eye field transcription factors characteristic of early neural retinal specification of
neuroepithelial cells. (C) Cultures 10 days post-induction of differentiation express PAX6,
RAX and SOX2. By day 18, RAX expression is down-regulated, and expression of PAX6 and
Nestin is maintained, characteristic of proliferating RPCs. (D) Importantly, cultures express
CRB1 by day 7 post-induction of differentiation and expression increases as the differentiation
continues. (E) Expression of photoreceptor precursor marker CRX begins by day 7 postinduction of differentiation. Additionally, these late-stage cultures express ganglion cell marker
BRN3A.
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Figure 4.5. CRB1-/- cultures trend toward higher levels of proliferation at day 14 postinduction of differentiation
(A) MTT assay analysis shows increased proliferation of CRB1-/- RPCs compared to CTRL
cultures, most markedly at day 14 of differentiation. (B) This correlates with increased
expression of CCND2 in CRB1-/- cultures at day 14 (C) Flow cytometric analysis of EdU and
Ki67 labeling show statistically significant alteration between the percentage of EdU+/Ki67+
RPCs in CRB1-/- cultures as compared to CTRL cultures at day 14. This analysis was
determined using the student t-test with Holm-Sidak method. *Statistically significant (p<0.05).
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Figure 4.6. Differences in the number of proliferating CRB1-/- and CTRL RPCs may
partially be explained by alterations in the expression of Wnt signaling pathway
components.
(A) No significant differences were detected in expression of Notch signaling pathway
components between CRB1 and CTRL RPC cultures at day 14 post-induction of differentiation
by qRT-PCR analysis. (B) Expression of all Wnt signaling pathway components assessed trend
toward increased Wnt pathway activation between CRB1-/- and CTRL RPC cultures at day 14.
Significant statistical differences in expression between CRB1-/- and CTRL RPCs were observed
in AXIN2, LEF1, TCF7, and WNT3a. This analysis was determined using the student t-test with
Holm-Sidak method. *Statistically significant (p<0.05).
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Figure 4.7. Loss of CRB1 may result in overproliferation of RPCs due to mislocalization
or altered expression of apical polarity complex components
Generation of specific post-mitotic neural retinal cells occurs in a temporally successive manner
from a pool of polarized RPCs. (A) Cell adhesion and polarity complexes, such as the Crumbs
and PAR complexes, are thought to be critical regulators of this transition because of their role
in asymmetric division, which generates daughter cells that can adopt differing fates during
development. Intrinsic asymmetric architecture ensures the inheritance of different cell fate
determinants upon division and is one mechanism by which cell specification occurs. (B) As the
only transmembrane component of these complexes, CRB1 is critical for maintaining polarity.
Loss of cell polarity, and consequently asymmetric division, is linked to excessive self-renewal,
which we observe in the CRB1-/- RPC cultures compared to the CTRL RPC cultures at day 14
post-induction of differentiation.
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Constructing a foundation
The work presented in the previous chapters represents only a small fraction of
what’s needed to address the current challenges in the field of AAV-mediated gene
therapies for IRDs. I presented data showing that ipsilateral subretinal
readministration of AAV2-hRPE65v2 in a large animal model appears to be safe
given that the injections target the same set of cells (Chapter 2) and demonstrated
that rational mutagenesis of the AAV8BP2 capsid is a simple and useful technique
for increasing the transduction efficiency of the vector in murine retinas (Chapter
3). Additionally, I describe my attempt to create a relevant in vitro model using
LCA8 patient-specific iPSC differentiated to retinal progenitor cells to study the
etiology associated with mutations of the CRB1 gene and probe for a discernible
phenotype that may be used to test the efficacy of gene augmentation strategies
(Chapter 4).

As I think is the case with many scientists, dissecting these challenges has led to
many more interesting questions in regards to the issues that I have tried to resolve
and the several other obstacles that exist surrounding development of new AAV
retinal gene therapies than it has to emerge with solutions to these problems.
Whether it’s brainstorming the possible scientific explanations for surprising
ipsilateral readministration results, performing multiple rounds of the same in vivo
experiment to ensure my data accurately reflects the mechanism of action I’m
exploring, or probing for the exact timepoint in cultures of RPCs in which
proliferation switches to differentiation, arriving at concrete answers is much more
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difficult than a scientific paper would lead you to believe. Often times, we’re unable
to reach the resolution we desire and must settle for partial clarification.

Regardless, these imperfect answers provide the foundation to continue to build
upon our knowledge. I’m as certain as a scientist can be that the definitive
remedies to these challenges are still years in the making. At this time, I can only
contribute my minor structural support to the foundation of data sown by other
fantastic groups of scientists. What I love about science and what keeps me
coming back, is that there will undoubtedly always be room for an addition or a
remodel of the stories we resolutely chip away at to uncover truths.
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Ipsilateral subretinal administration of AAV: confronting our current
assumptions
Our understanding of the immune response to rAAV administration comes from
hundreds of papers that consistently frustrate those of us that work in the gene
therapy field. Pre-existing neutralizing antibodies can induce humoral and cellular
immune responses that upon systemic and occasionally local delivery of rAAV that
in the best case scenario targets and abolishes the AAV capsid before it even has
a chance to transduce a cell; in the worst case scenario the harmful immune
response destroys healthy tissues transduced by rAAV and/or expressing the
transgene and results in the production of pro-inflammatory cytokines that have
the potential to incite damage to body tissues and organs outside of the context of
AAV. We know that the eye is an immune privileged area – it attempts to limit local
immune and inflammatory responses through a combination of local and systemic
mechanisms. However, it is not absolute failsafe. This has been thoroughly
demonstrated in models of induced uveitis, when even small numbers of adoptively
transferred activated T-effector cells break privilege (Caspi, 2006).

So, it is with no wonder that approaches to readminister rAAV to contralateral eyes
took all the extra precautions when gathering pre-clinical data. Even now, upon
knowing that rAAV can indeed be safely administered to contralateral eyes
humans, even in the setting of pre-existing serum NAbs, no one to our knowledge
has yet to attempt ipsilateral rAAV. As mentioned previously, there are scenarios
in which it would be desirable to treat initially injected retinas with a subsequent
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injection. These include targeting regions of the retina not targeted in the first
injection to treat a larger area or targeting the same set of cells targeted in the first
injection to boost transgene expression levels. We set out to test the safety through
evaluation of the structural and immune consequences of these situations in a
large animal model that most closely anatomically resembles the human retina –
NHPs. And what we expected to see and what we actually observed ended up
surprising us.

The three NHPs used in this study were administered two subretinal injections of
AAV2-hRPE65v2 in each eye. To reflect the different circumstances described
above the injections either completely overlapped, partially overlapped, or did not
overlap at all. We expected the retinas of the monkeys with overlapping injections
to be the most vulnerable to physical damage caused by compounding the
mechanical nature of the injections in the exact same region and subsequently the
development of a harmful immune response upon structural alterations that would
promote access of circulating cells or foreign antigens. Contrastingly, these
animals appeared to minimal inflammation and retinal damage. On the other hand,
the monkey that had injection regions that did not overlap didn’t fare as well. This
NHP showed the greatest inflammation and retinal structural havoc in addition to
activation of both a humoral and cell-mediated immune response.

These results can be taken in several different future directions. Firstly, these
NHPs were not administered oral prednisone, which is given to their human
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counterparts before and after contralateral injections. Use of systemic steroids may
resolve much if not all of the residual inflammation we noticed in the two monkeys
with overlapping injection sites and could also lessen the harmful effects observed
upon ipsilateral administration to separate areas of the retina. Secondly,
performing this study with RPE65-mutant dogs could provide information about the
efficacy of a second ipsilateral injection. With unaffected NHPs, we were not able
to explore the consequences on visual function. With blind dogs, we’d be able to
perform functional vision test to ascertain if ipsilateral readministration was more
helpful or harmful to vision than single contralateral injections. Lastly, it would be
interesting to explore to outcome of using different AAV serotypes for the initial
and subsequent injection and how the observations we made in this study compare
to such a scenario.
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Expanding our AAV capsid toolbox one base substitution at a time
The continued generation of new or modified AAV serotypes has been helping
researches to hone the ability to specifically target a tissue or particular cell type
of interest with high transduction efficiency. In combination with other advances,
such as alterations to the expression cassette components, we could soon have
the technology to potently target smaller subsets of particular cell types, such as
P-type retinal ganglion cells (RGCs), one of five main classes of RGCs which
vary significantly in their size, connections, and responses to visual stimuli (Bassi
and Lehmkuhle, 1990). This study began with one unassuming question: can we
easily optimize an AAV capsid to be more potent?

Based on previous research using the AAV8 serotype, we decided to mutagenize
capsid-surface tyrosine residues in AAV8BP2. This capsid was pulled out of an in
vivo screen performed in mice to more efficiently target the retinal bipolar cells of
the inner nuclear layer. Unfortunately, directing this capsid to potently transduce
murine retinal bipolar cells did not translate to large animal studies. This result can
be attributed to one of four AAV transduction limitations: 1) the absence or low
abundance of cellular surface receptors required to get into a cell, 2) inability to
escape the endosomal and subsequent lysosomal degradation, 3) difficulty
translocating to the nucleus for vector uncoating, or 4) slow conversion of the
ssDNA genome to a usable dsDNA template for mammalian cell transcription.
Mutagenesis of AAV8BP2 capsid tyrosine residues is most likely to have a positive
effect on transduction efficiency if the discrepancy between murine and NHP
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retinas occurs because of constraint 3. This is due to the chemical structure of
tyrosine, which subjects the residue phosphorylation by ubiquitin E3, marking the
capsid for proteasomal degradation.

Upon mutating two tyrosine residues to phenylalanine, we observed that only one
of these mutations was successful at improving AAV8BP2 transduction efficiency
in vitro and in vivo while the other mutation actually reduced the transduction
efficiency of AAV8BP2 in vivo. One additional aim of the study was to determine if
these mutations changed the cellular tropism of AAV8BP2. Regrettably, in the
name of trying to observe discernible, significant differences in transduction, the
injected vector concentrations were too low to penetrate into the INL from the
subretinal space. Future experiments include performing in vivo analysis with a
higher vector dosage to see if this changes the distribution throughout the retina
to infiltrate into deeper cell layers and repeating the in vivo analysis of intravitreal
administration in younger mice to determine if our data was an artifact of retinal
degeneration. Given these results, going to testing transduction efficiency and
cellular tropism in a large animal model may provide differing data to what has
already been published using AAV8BP2.

It would be worth exploring if other established AAV serotypes could also benefit
tyrosine mutations. AAV7m8, which has a single surface-exposed tyrosine, has
quickly become a favored serotype in the retinal gene therapy world due to its
ability to efficiently transduce a myriad of cell types, but could its potency be
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furthered or its ability to transduce specific retinal cells enhanced? As the use of
lower vector dosages is always more advantageous, these findings could have a
significant impact the amount of AAV vector required for efficient transduction.
Mutagenesis of amino acid residues does not have to stop at tyrosine. Serine,
threonine, and lysine mutations have all been shown to boost transduction
efficiency of retinal cells with varying AAV serotypes. Perhaps a specific
combination of the mutations is most effective. We can easily alter the AAV capsid
by employing rational mutagenesis without the need for extensive capsid libraries
and more niche expertise.
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Personalized IRD models can be used to evaluate developmental etiologies
Although the study of IRDs benefit from numerous spontaneous and genetically
engineered animal models compared to diseases of other organs, the complex
presentation and heterogenous nature of IRDs, even between individuals
harboring the same mutation in the same gene, makes it difficult to ascertain the
natural history of many IRDs and, in turn, to develop new therapies. One
proposed solution for this has been to create in vitro IRD models using patientspecific iPSC. If we can use these to generate retinal cells of interest, we can
begin to probe the basic biology of IRD etiology, particularly for congenital IRDs
such as early onset RP and LCA. These models also initiate the addressing of
issues related pre-clinical testing of new therapies and extrapolation of the
results obtained in animals to humans, which don’t always provide an accurate
appraisal of safety and efficacy.

In this study, we aimed to generate RPCs to model CRB1-associated LCA. By
mirroring the signaling pathway inhibition of in vivo organogenesis and probing
for specific developmental markers, we were able produce adherent 2D cultures
to test the hypothesis that LCA8 pathology begins at the very earliest stages of
retinal patterning, at the switch from progenitor proliferation to terminal
differentiation. However, this proved to be much more difficult than initially
anticipated. Firstly, we needed to try and pinpoint the time during the
differentiation in which this shift occurred. We then had to perform several assays
on multiple differentiations to determine if we could discern meaningful and
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significant differences between our CRB1-/- and CTRL cultures. Due to inherent
irregularities among cultures of the same genotype and other variables, including
cell passage number, X-inactivation in iPSC generated from female patients,
culture confluency at initiation of the differentiation, and acclimation of cells to
new culture conditions, we had a particularly difficult time obtaining consistent
results.

In addition to our experimental strategy, we did not employ the use of two
technologies now common and practically expected when working with iPSC –
generation of 3D organoids and isogenic control cell lines using CRISPR/Cas9.
Both of these would have been useful in this study given that 1) CRB1 mutations
affect multiple retinal cell types and result in structural disorganization of neural
retina, which could be further studied with self-organizing, laminated optic cups
and 2) the suggestion that modifying alleles affect CRB1-associated IRD
phenotypes and the inconsistent behavior in genetically variable cell lines, which
could have been by creating isogenic control cell lines.

Future directions for this study are broad ranging. I believe it is important to
perform flow cytometry to determine the percentages of progenitors and other
retinal neurons present in these cultures at different timepoints to determine the
relative quantification of the number of cells of interest we are working with and
to assess the reliability of the differentiations. Studying the polarity differences
between CRB1-/-and CTRL cultures could also be informative given CRB1 plays
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a critical role in the formation of an apical polarity complex. It would also be
interesting to define how expression of the Wnt signaling pathway components
change over the course of the differentiation, particularly because our strategy
involves small molecule Wnt inhibition. Our findings may not be giving us an
accurate representation of CRB1-associated modifications because of this. This
could be evaluated by determining if the observed hyperproliferative phenotype
could be altered by altering Wnt inhibition.
Using patient-specific iPSC to study IRDs is a powerful tool if you know how to
wield it correctly. One of the major lessons I learned from this study is the
importance of analyzing your data diligently and recognizing when it’s time to
change your strategy.

Recent findings from Quinn et al., suggest that CRB2 protein precedes the
expression of CRB1 in the developing human retina and that onset of CRB1
expression occurs in the second trimester of human fetal development as the
retina matures (2019). This information provides new insight into future study of
CRB1-associated IRDs. During the second trimester, mitosis has ceased in
approximately 77% of the retina, and this only continues to increase as gestation
increases (Provis et al., 1985). Interestingly, cell densities are elevated in the
retina at this time. Towards the end of the second trimester, cell densities and
numbers decline, suggesting naturally occurring cell death is largely responsible.
Given the findings of Quinn et al., CRB1 may actually be responsible for this
observed apoptosis. The thickened retinas of CRB1-deficient patients could be
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explained by the failure to initiate apoptosis rather than increased proliferation of
retinal progenitor cells.
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